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INTRODUCTION 
Epidural  anesthesia  is  one  of  the preferred  modes of  regional  
anaesthesia for lower limb orthopedic surgeries. This  technique  provides  not 
only peri-operative surgical anaesthesia but also post-operative  analgesia(1,2)  for  
lower limb orthopedic surgeries. 
In year 1885, experiment of James Leonard Corning, helped in 
development of epidural and spinal anesthesia(3)  . 
In 1901, the first epidural analgesia given by Jean Anthanase Sicard, who 
introduced cocaine through the sacral hiatus for the treatment of sciatica and 
tabes.  
In 1921, the first time segmental peridural anesthesia, under the name of 
Metameric anesthesia was given by Fidel Pagés, a Spanish military surgeon. 
In 1931, Italian Professor Archile Mario Dogliotti, described the practical 
technique for administering   local anaesthetic for lumbar segmental anesthesia.  
In 1932, Alberto Gutierrez Physician, described the hanging drop 
technique to identify the epidural space. 
In 1949, Manuel Martinez Curbelo of Cuba , inserted  a small ureteral-
catheter into epidural space via tuohy needle to  provide continuous-lumbar 
epidural analgesia.  
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Epidural anaesthesia reduces physiological stress related to surgery and 
improves surgical outcomes, gives good postoperative pain relief. Effective pain 
control is important care needed for surgical patients. Adequate post operative 
pain relief is an integral part of anaesthesia . Inadequate post operative pain  
relief can increase the  patient stress , morbidity and mortality . Adequate 
postoperative pain relief will be helpful in early ambulation of the patient  as 
well as hospital discharge.      
The newer amide local anaesthetic ropivacaine has minimal 
cardiovascular and central nervous system toxicity as well as a lesser propensity 
of motor block during  epidural analgesia.(4,5) 
Nowadays, the use of adjuvant with local anesthetics prolongs the 
duration of action, produce early  onset of action of local anaesthetic , better  
sedation, maintain  stable haemodynamics,  also has ability to provide  prolonged  
post-operative analgesia  which are the main desirable qualities of an adjuvant in 
neuraxial anaesthesia 
In 1973, Pert and colleagues reported on the presence of opioid receptors 
in high  density in the dorsal horn of the spinal cord and this fact  helped  Sabbe 
and Yaksh  for the use of spinal opioid for first time  
Fentanyl  is a synthetic  opioid used  as an adjunct for epidural local 
anaesthestics  to reduce dose requirement of local anaethestics and to achieve the 
desired anaesthetic effect (6,7). Using  opioid as additive to local anaesthetic  
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provides a dose sparing effect of local anaesthetic and superior analgesia but 
there is an increased chances of side effects such as  nausea, vomiting, pruritis, 
urinary retention and respiratory depression.(8,9) 
In 1999, Dexmedetomidine was first introduced as a short term  
sedative agent for adult patients on mechanical ventilator in ICU (10). 
Dexmedetomidine (11 – 13)   is a new drug with selective α2-adrenoceptor agonist 
when used as adjuvant to regional anesthesia showed analgesic, sedative, 
anxiolytic, sympatholytic properties  and  causes minimal respiratory depression. 
Dexmedetomidine produces manageable hypotension and bradycardia , but this 
drug  doesnot  have  opioid-related side effects like, pruritis ,urinary retention,  
vomiting, respiratory depression.[14,15]   . 
Aim of my  study is to  evaluate  and compare the efficacy, analgesic 
effects, postoperative analgesia of epidurally administered dexmedetomidine or 
fentanyl along with ropivacaine for patients undergoing lower limb orthopedic 
surgeries.  
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AIMS AND OBJECTIVES 
AIM  
To evaluate and compare the efficacy, analgesic effects, postoperative 
analgesia of epidurally administered dexmedetomidine or fentanyl along with 
ropivacaine for patients undergoing lower limb orthopedic surgeries  
OBJECTIVES  
Comparative study of dexmedetomidine or fentanyl as adjuvant to 
epidural  ropivacaine for lower limb orthopedic surgeries with respect to 
Ø Time of onset of sensory block at T10,  
Ø Maximum sensory level achieved , 
Ø Time taken for complete  motor blockade, 
Ø Sedation score 
Ø Total duration of analgesia,  
Ø Time of first rescue analgesia , 
Ø Haemodynamic parameters, 
Ø Side effects .  
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ANATOMY OF VERTEBRAL CANAL(16) 
There are seven cervical, twelve thoracic, five lumbar vertebrae, fused  
segment of five sacral and four coccygeal vertebrae present in the vertebral 
column .  
CERVICAL VERTEBRA   
The typical cervical vertebral body ( C3–6  vertebrae )  having  a small 
flattened triangular body with  relatively large vertebral foramen.  The transverse 
process is short and which has the foramen transversarium which transmits the 
vertebral vessels. 
The largest and most inferior vertebra is the cervical (C7) vertebra. C7 has 
a large spinous process that protrudes posteriorly toward the skin at the back of 
the neck. This spinous process can be easily seen and felt at the base of the neck, 
making it a prominent landmark, called as vertebra prominens. 
THORACIC VERTEBRA 
Typical thoracic vertebral body  (T 2 – T 8 vertebrae ) is heart shaped ; 
the upper two vertebrae bodies show  similarity to that of  cervical vertebra, 
whereas the lower thoracic vertebrae bodies show similarity to that  of lumbar 
vertebral bodies.  The spinous process of the mid thoracic vertebrae are caudally 
angulated, hence while performing a thoracic epidural in a midline approach it is 
necessary to give a markedly cephalad angulation of the needle for passing in-
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between the spines. The spines of T 11 and T 12 are nearly horizontal, short and 
square shape as like lumbar spines. 
LUMBAR VERTEBRAE 
The body of the lumbar vertebra is large and kidney-shaped. The vertebral 
foramen is  roughly triangular in shape, larger in size  than  the thoracic vertebral 
foramen but smaller than  the cervical region. The pedicles are thick, with 
shallow superior notches. The transverse processes are slender; they increase in 
length from Ll to L3 and  then become shorter from L4-L5. The laminae are 
short, broad  does not overlap each other as in the thoracic region. Lumbar 
spinous processes are horizontal and oblong.   The 5th lumbar vertebra forms the 
lumbosacral angle which  is  wedge-shaped,  deeper in front than behind.  
The line that joins the top of the iliac crests,  the intercristal line  usually 
passes through the body of the 4th lumbar vertebra, and is therefore a useful 
landmark. The space above this line is usually the L3/4 interspace, and that 
below is usually the L4/5 interspace. Widening the gap between the lumbar 
spinous processes by flexing patient ‘s spine makes identification  of interspace 
for lumbar puncture easier. 
The vertebal column is bound together by several ligaments which give it 
stability and elasticity.  
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They are  
· Anterior Longitudial ligament –   It runs along the anterior aspect  of the 
vertebral  bodies from above downwards ,  extending from C2 to the upper 
sacral vertebra.  It is adherent to the  intervertebral disc 
· Posterior longitudinal ligament  - It runs  along the posterior surface of the  
vertebral bodies 
·  Supraspinous ligament – It is a  strong fibrous cord connecting the apices 
of spinous processes,  ascends from sacrum to C7 vertebra. Then it extends  
upto external occipital protruberance as the ligamentum nuchae. 
· Interspinous ligament –It is a thin membranous ligament connecting the  
shaft of spinous processes, joining  anteriorly with ligamentum flavum and 
posteriorly with supraspinous ligament. 
· Ligamentum flavum – It is also called as ‘yellow ligament’, comprising of 
yellow elastic fibres and connects adjacent lamina by attaching  downward  
edge of the above  lamina  to the cephalad edge of the lamina below. 
SPINAL CANAL :       
          The spinal cord is a continuation of  the medulla oblongata, begins at the 
level of the foramen magnum and ends below as the conus medullaris. It is  
cylindrical in shape, 45 cm in length in adults. Spinal cord tapers into conus 
medullaris and which continues as a  thin thread like  structure called, filum 
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terminale is which attached to the coccyx. The filum terminale is mainly pia 
mater invested in a sheath of dura . At birth it ends at the lower border of L3 and 
rises to end in adult life at the lower border of L1.  
 There are totally 31 pairs of symmetrically arranged spinal nerve roots:  
Cervical - 8, Thoracic - 12, Lumbar - 5, Sacral - 5and Coccygeal - 1. The cauda 
equina is formed by elongation of nerve roots of lumbar and sacral region before 
they exit from the intervertebral foramen. 
Spinal cord has three meningeal covering  – dura mater, arachnoid mater 
and pia mater . 
Dura mater – contains two layers -  the inner (meningeal) layer of the 
cerebral dura, which is made up of dense fibrous tissue and  the outer (endosteal) 
layer of the cerebral dura  at the level of  foramen magnum  merges with the 
periosteum enclosing the skull, and then  continues as  periosteal lining of the 
vertebral canal. 
The dura ends at the second sacral segment (variably L5–S3). It attaches 
to the coccygeal periosteum and covers the filum terminale. Anteriorly the dura 
is attached to the posterior longitudinal ligament and extends around the nerve 
roots laterally but it is free posteriorly. 
Arachnoid mater – delicate, nonvascular thin membrane closely lining 
the duramater.  
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Pia mater –  highly vascular connective sheath that closely covers the 
spinal cord. The anterior part is thickened (linea splendens) and  laterally forms 
ligamentum denticulatum and attached to the dura  . Posteriorly it attaches to the 
dura by an incomplete sheet of pia (posterior subarachnoid septum).  Inferiorly it  
pierces the  dural sac and then attaches  to the coccyx with a covering sheath of 
dura. 
Subdural space  
It is a potential space between the arachnoid mater and the duramater 
which contains thin serous fluid. 
Subarachnoid space  
It is anatomical space between the arachnoid mater and piamater contains 
cerebrospinal fluid (CSF), spinal nerves, a trabecular network between the two 
membranes, blood vessels that supply the spinal cord .  Although the spinal cord 
ends at the lower border of L1 in adults, the subarachnoid space continues upto 
S2. 
EPIDURAL SPACE  
Epidural Space is an anatomical space of the spinal canal, which is  
outside the dural sac within the bony cavity. 
It  is a negative  potential space  extending  from foramen magnum to 
coccyx communicating laterally with paravertebral space through the 
intervertebral foramina.  
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Boundaries 
Superiorly - The foramen magnum where the dural  periosteal layer of skull 
continues as  periosteal  layers of vertebral canal.  
Inferiorly -  The Sacrococcygeal ligament.  
Anteriorly - The posterior aspect of the vertebral bodies with posterior 
longitudinal ligament and the intervertebral disc.  
Posteriorly - Ligamentum flavum and the laminae of vertebrae.  
Laterally -  The pedicles of vertebral arch  and the intervertebral  foramina 
containing their neural elements.  
 
Electron microscopic picture of epidural space in relation to dura(18) 
CONTENTS OF THE EPIDURAL SPACE  
The epidural space contains nerve roots  with their dural sleeves, 
lymphatics, fat, areolar tissue and blood vessels,  including  the Batson venous 
plexus.  
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DISTANCE FROM  THE SKIN TO EPIDURAL SPACE 
Skin, subcutaneous tissue, supraspinous and interspinous ligaments, 
ligamentum flavum are  the following structures pierced  by the needle before  
entering   into the epidural  space.  
The depth of the epidural space varies according to the body habitus.  
The distance can be less than 4cm in thin patient  and greater than 8cms in 
the obese.  
Thickness of ligamentum flavum: 
Site                 Thickness of ligament 
Cervical         -        1.5 to 3.0 mm 
Thoracic        -         3.0 to 5.0 mm 
Lumbar         -         5.0 to 6.0 mm 
Caudal          -         2.0 to 6.0 mm 
IDENTIFICATION OF EPIDURAL SPACE (17) 
Various types of techniques are there to locate the epidural space which 
lies between the posterior longitudinal ligament and the ligamentum flavum. 
1. LOR -Loss of resistance (sudden ) technique with air or preservative free 
normal saline 
2.  Movement of bubble on odom‘s indicator  
3.  Hanging drop technique  
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4.  Pop off feeling 
5.  Nerve Stimulation 
6.  Ultrasound- To locate the depth of the epidural space  
7.  Macintosh ‘ s extradural space indicator  
8.  Mactintosh Spring loaded needle  
9.  Oxford epidural space indicator 
10.  Fluoroscopy 
11.  Epiduroscopy 
 
 
A. Median approach. Angle and the direction of the needle for the 
median and paramedian approaches for spinal andepidural 
techniques.  
B.  Paramedian approach. Angle and the direction of the needle for the 
median and paramedian approaches for spinaland epidural 
techniques.(16) 
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Volume of local anaesthetic required for epidural anaesthesia :           
Volume of local anaesthetic injected in milliliters per number of 
dermatomes blocked . 
Cervical – 1.5 ml  
Thoracic – 2ml  
Lumbar – 2.5 ml                                                                                                                                                  
Site of Action 
When a solution of a local anaesthetic is injected into the epidural space, 
it may act   
1. On the nerve roots in the epidural space. 
2.  On the nerve roots  in the paravertebral spaces after they have shed their 
dural sheaths. 
3.  On the nerve roots in the subarachnoid space after inward diffusion of 
drug across the duramater 
4.  Diffusion into the subperineural and subpial spaces ,so- called  
‘ink-cuff zone’  
Following fibers are  blocked : 
1. Anterior nerve roots  
2. Posterior nerve roots  
3. Mixed spinal nerves  
4. White and grey rami communicates  
5. Visceral afferents accompanying sympathetic fibers and  
6. Certain descending pathways in spinal cord  
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PHYSIOLOGY OF EPIDURAL ANAESTHESIA (18) 
PHYSIOLOGICAL  EFFECTS 
The spinal nerve roots are the site of action of the local anaesthetic in the 
epidural space. The segmental nerve roots  contains somatic-sensory, motor and 
autonomic-nerve fibres. Both somatic and visceral pain stimuli are interrupted by 
sensory blockade, whereas motor blockade provides muscle relaxation.   
      Differential nerve block refers to varying sensitivity of the nerve fibers 
with different functions, to the local anaesthetic . Thin, myelinated C sensory and 
post ganglionic  fibers  are blocked at the lower concentration of drug, followed 
by pain, touch, and  lastly motor fibers.  
Sequence of events occurs as following : 
• Sympathetic block (vasodilatation) 
• Loss of pain and temperature sensation 
• Loss of proprioception  
• Loss of touch and pressure sensation 
• Loss of motor function  
The physiologic effects of epidural blockade on various system : 
CARDIOVASCULAR SYSTEM  
The effects  depend on the level and the degree of sympathetic blockade.  
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The preganglionic sympathetic innervation plays a important role in 
regulating regional blood flow. Sympathetic blockade results in loss of 
vasomotor tone; decrease in blood pressure therefore cause considerable changes 
in blood flow to organs, which depends  on the level blockade.  
Post ganglionic sympathetic nerve  fibers plays a vital role in  controlling   
vascular tone and cardiac function.  Blockade of  cardiac afferent and efferent 
sympathetic fibres  produces loss of chronotropic and inotropic drive to the 
myocardium.  
Vascular absorption of  local anaesthetic and vasoconstrictor may 
produces  significant haemodynamic changes following epidural anaesthesia. 
Local anaesthetic  produces  significant reductions in heart rate. The left 
ventricular contractility decreases with an approximate 15% reduction of stroke 
volume when C5 to T5 fibres blocked. 
RESPIRATORY SYSTEM 
· Epidural blockade upto midthoracic levels has little effect on respiratory  
function in patients without pre-existing disease 
· Lung volumes (Vital capacity, Tidal volume), Resting minute-ventilation and 
dead-space are unaffected. 
· Continuous epidural analgesia in the postoperative period may increases 
functional residual capacity and improve the postoperative pulmonary 
function. 
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GASTROINTESTINAL SYSTEM 
· Effects are mainly due to the sympathetic blockade of splanchnic fibres  at 
T5-L1 levels.  
· Unopposed parasympathetic nervous system activity  produces  increased 
secretions, peristalsis, relaxation of sphincters. 
· Gastrointestinal motility returns more rapidly when epidural analgesia is 
administered in the postoperative period with a local anaesthetic. 
· epidural analgesia for postoperative pain relief  improves gastric emptying 
and intestinal motility after abdominal surgeries. 
· Nausea is a relatively a common  problem following neuraxial 
anaesthesia.  
RENAL SYSTEM 
· Epidural anaesthesia has little effect on renal blood flow . Renal blood 
flow is maintained through auto regulation, therefore epidural anaesthesia 
produces very minimal change on renal function.  
· Neuraxial blockade at the lumbar level has been reported to impairs 
detrusor   function secondary to blockade of the S2-S4 segments.  Bladder 
distension and urinary retention occurs till the blockade wears off. 
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NEUROENDOCRINE STRESS RESPONSE 
· various  metabolic and endocrine functional changes  are associated with 
the stress  response to surgery  
· Epidural anaesthesia inhibits changes produced by surgical stress by 
inhibiting catecholamines and other stress hormones release .  
Epidural anaesthesia  inhibit hyperglycemic response to surgery  which 
occurs by  inhibition of the catabolic hormones, reduces hepatic glycogenolysis 
and  increases  gluconeogenesis and also  increases  lipolysis, which result into  
reduction  of plasma levels of free fatty acids, and glycerol concentrations 
INDICATIONS FOR EPIDURAL ANAESTHESIA : 
(1)  Surgical anaesthesia 
(2)   Postoperative pain relief 
(3) Palliation in acute pain emergencies 
Surgical anaesthesia 
1. Cervical epidural anasethesia - Thyroidectomy and Mastectomy 
2. Thoracic epidural anasethesia - Upper abdominal surgeries, Thoracic  
surgeries. 
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3. Lumbar  epidural anasethesia - Obstetrics and gynaecological surgeries 
and labour analgesia. Orthopaedic 
surgeries like major hip/knee surgery,                                            
repair of pelvic fractures, femur and tibial 
fracture fixation. Urological surgeries 
involving prostate, bladder and                                         
ureters. 
4. Paediatric caudal  anasethesia  - lower abdominal  and lower limbs 
surgeries . 
Palliation in acute pain emergencies 
Chemotherapy – related peripheral neuropathy pain 
Chronic benign pain syndrome 
       Radiculopathy / spondylosis   
CONTRAINDICATIONS FOR EPIDURAL ANAESTHESIA 
Absolute : 
1. Patient refusal 
2. Local site infection  
3. Bleeding diathesis and  Coagulopathy 
4. Increased intracranial pressure  
5.  Uncorrected Hypovolemia and shock  
6.  Fixed cardiac output state 
7. Allergic to ester/amide local anaesthetic. 
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Relative : 
1. Pre-existing neurological disease 
2. Severe deformity of spine 
3. Uncooperative patient 
4. Sepsis  
COMPLICATIONS OF EPIDURAL ANAESTHESIA 
IMMEDIATE COMPLICATIONS 
1. During Insertion   -  needle or catheter penetrate blood vessel,  duramater, 
neural tissue, broken catheter  
2. Systemic toxicity associated with inadverent intravascular injection 
3.  Subdural injection of drugs, Total spinal anaesthesia 
4. Inadequate analgesia  - total / partial Failure 
DELAYED COMPLICATIONS 
1. Damage to nerve roots by needle, Ischaemia of  spinal cord.  
2. Neurological – Epidural Abcess, Epidural Haematoma, Chemical 
meningitis 
3. Post Dural Puncture Headache  ( accidental dural puncture ).  
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FACTORS INFLUENCING THE EPIDURAL BLOCKADE 
· Physiology of nerve conduction  
· Age 
· Pharmacology of the local anaesthetic.  
Potency of the drug 
     Duration  action of the drug  
· Additive to local anesthestics  
1. To improve the quality of epidural anaesthesia and analgesia. 
2. It reduces onset time of local anaesthetic. 
3. Decreases the requirement  of local anaesthetic dose. 
4. Increases the duration of the local anaesthetic and analgesic effect 
5. Modulates the immune stress-response to thoracic surgery 
6. By reducing cytokine response, it further reduces pain sensitivity. 
PHYSIOLOGY OF NERVE IMPULSE(19) 
Nerve conduction is produced by  the propagation of an electrical 
impulse, which occurs due to  the rapid movement of ions across the nerve cell 
membrane, resulting into  production of  an action potential. 
The principal ions in generating the action potential are sodium and 
potassium. Polarization is maintained  by higher concentration of sodium 
extracellularly and potassium in higher concentration  intracellularly  
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The active sodium–potassium pump transports sodium out and potassium 
into the cell to  restore ions to appropriate side , inorder  to maintain the gradient 
at the resting state. At the  resting nerve membrane,  permeability  to potassium 
ions  slightly more than  to  sodium  and the leakage of  ions makes it more 
negative within the cell than outside, which  maintains  a negative resting 
membrane potential of  – 60 to    –70 mV.  
When stimulus  occurs, conduction of nerve impulse is along the axon of 
nerve, causing depolarization. If the depolarization exceeds the threshold  
potential ( – 60 mV), a sudden influx of sodium occurs by opening of sodium ion 
channel. As result of sodium ion influx, intracellular charge become more 
positive and the transmembrane potential  becomes positive (> +30 mV) and 
action potential occurs. This electrical event continues till nerve terminal and 
propagation of  the action potential occurs  along the whole length of the nerve.  
Repolarization occurs by the efflux of potassium out of cell , makes the 
membrane potential less positive , restores polarization of membrane .Thus the 
cell tries to return to its resting state.  
The local anaesthetic acts upon voltage - gated sodium channels and 
produces conduction blockade.  
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Figure – 5  voltage - gated sodium channels - local anesthetic molecules 
selectively binds to sodium channels in inactivated-closed states, stabilize these 
channels in this configuration and prevent their change to the rested-closed and 
activated-open states in response to nerve impulses and thus produces conduction 
blockade. (19) 
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PHARMACOLOGY OF ROPIVACAINE(19,20) 
Ropivacaine hydrochloride  
It belongs to pipecoloxylidides group of local anaesthetic with the 
piperidine nitrogen atom having a propyl group which was synthesized in 1957. 
Ropivacaine  is an  amide  type local anesthetic similar to bupivacaine in  
structure.  In contrast to Bupivacaine, Ropivacaine a pure S (-) enantiomer, and 
has reduced toxicity.  Ropivacaine  acts on different ion channels such as 
sodium, potassium and calcium channels  with different affinity that result in 
greater reduction in  cardiovascular toxicity and neuronal toxicity . 
It produces differential blocking effect on nerve fibers since it produces 
anaesthesia at high doses and at lower doses it produces analgesia 
CHEMICAL FORMULA 
S-(-)-1-propyl-2', 6'-pipecoloxylidide hydrochloride monohydrate   
STRUCTURAL FORMULA  
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PHYSIOCHEMICAL PROPERTIES 
Drug substance  : White crystalline powder, 
Molecular weight : 328.89. 
Molecular formula  : C17H26N2O·HCl·H2O 
pKa   : 8.1 
Lipid solubility : Intermediate between bupivacaine and mepivacaine 
Specific Gravity : 1.002 – 1.005 at 25˚C  
PHARMACOKINETICS  
ABSORPTION 
The variation in the  plasma concentration depends on the route of 
administration of drug , dosage of the drug  and  injection site vascularity. 
Ropivacaine shows a linear pharmacokinetics,  Cmax is proportional to the dose. 
When given extradural its absorption is biphasic (t1/2 is 4mins and 4 hrs) and 
complete. Elimination of ropivacaine is mainly depends on absorption which is 
the rate limiting step. Epidurally given drug has longer t1/2 compared to 
intravenous route. The terminal half life of ropivacaine is1.8hrs after IV route of 
adminstration.  
DISTRIBUTION  
Ropivacaine is highly protein bound particularly to 1-alpha  glycoprotein 
and unbound fraction is about only 6%  . It crosses easily through the placenta 
and degree of binding to the plasma proteins in fetus is less compared to mother. 
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METABOLISM 
Ropivacaine is metabolized in the liver, mainly by aromatic hydroxylation 
which mediated by cytochrome P450 (CYP) 1A2 to 3-hydroxy ropivacaine and          
N- dealkylation by CYP3A4 to 2', 6'-pipecoloxylidide (PPX) .  
The main metabolite is 3-hydroyropivacaine excreted after conjugation. 
Other metabolites are 4-hydroxyropivacaine and 2’, 6’-pipecoloxylidide. 
ELIMINATION  
If given by intravenously , about 86% of the dose excreted via urine, out 
of which only 1% is  unchanged fragment.  The PPX(2’, 6’- pipecoloxylidide) 
has longer t1/2 and lower clearance after infusion through epidural route .   
Clearance – unbound ropivacaine  : 13.94L/h/Kg  
Clearance – Total ropivacaine  : 0.555L/h/Kg 
Total plasma clearance  : 387 ± 107 mL/min 
Unbound plasma clearance  : 7.2 ± 1.6 L/min 
Renal clearance   : 1ml / min 
Terminal t1/2 of PPX   : 17.8 hrs 
Terminal t1/2 of ropivacaine  : 3.3hrs 
PHARMACODYNAMICS 
Because of its stereo selective property, ropivacaine has fewer 
propensities for cardiac and CNS adverse effects It has similar efficacy to levo 
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bupivacaine and bupivacaine in blocking peripheral nerve. When given 
neuraxially it is less potent than bupivacaine. It is associated with higher  
incidence of   lower grade motor blockade when compared to bupivacaine. 
Because of its lower  grade motor blockade, it has reduced potential for CNS and 
cardiac adverse effects. It is a new agent of choice for regional anaesthesia 
currently .            
Because of less lipid solubility than bupivacaine, it minimally penetrates 
the large myelinated Aβ motor fibres, this shows  its highly specific action on  
Ad and C nerves  rather than Aβ fibres .  
CARDIOVASCULAR SYSTEM 
At therapeutic doses, ropivacaine can produce changes in cardiac 
contractility, excitability, conduction, refractoriness and peripheral vascular 
resistance. 
At toxic doses,  it depresses the  cardiac conduction , which may result  in 
ventricular arrhythmias ,atrioventricular block  and  cardiac arrest. 
It produces peripheral vasodilation , that leading to decrease in the  blood 
pressure and cardiac output .  
Ropivacaine causes significantly less depression of cardiac contractility, 
hence cardiac toxicity due to ropivacaine is less when compared to the 
bupivacaine.   
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CENTRAL NERVOUS SYSTEM 
Ropivacaine can produce stimulation or depression of central nervous 
system  or both. Apparent central nervous  stimulation is manifest as restlessness, 
shivering, tremors, progressing to convulsions, followed by depression and 
coma,  ultimately  progressing  to respiratory arrest. 
However, ropivacaine may have a primary depressant effect on the  higher 
centers and medulla . The depressed stage may occur without any prior excited 
stage. 
MECHANISM OF ACTION  
Ropivacaine  produces reversible  blockade  of   sodium  entry into the 
nerve cell membranes, which produces  decrease in  membrane permeability to 
sodium ions. Ultimately the threshold for  nerve excitability increases, thereby 
slowing the nerve conduction and decreasing the rate of  rise of the action 
potential. 
INDICATIONS 
Local infiltration 
Epidural anesthesia and analgesia 
Spinal anesthesia 
Peripheral nerve blocks 
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CONTRAINDICATIONS : 
Hypersensitivity, 
Intravenous regional anaesthesia, 
Paracervical block in obstetric anaesthesia, 
Hypovolemia,  
Premature children.  
PRECAUTIONS 
· Accidental intravenous administration results in cardiac arrest and 
convulsions. 
· Retrobulbar block because of less clinical evidence. 
· Patient with poor general condition 
· Liver disease. 
· Kidney dysfunction. 
· Acute porphyria 
DOSAGE AND ADMINISTRATION 
For Spinal block, administration of 2-3ml of 0.75 % ( 7.5mg/ml) with 
doses between 15-22.5 mg  at L3-L4 interspace  results in sensory block upto T4 
or T5.  
For Epidural block, administration of 15 -20 ml  of 0.5 %  or 0.75 %  
provides epidural anaesthesia and  with  6-14 ml of 0.2% ropivacaine provide 
adequate analgesia . 
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For Caudal block, administration of 1mg/kg, 0.2% or 2mg/ml produces a 
level belowT12. 
For  peripheral nerve blocks , dosage of 3 mg/kg is administered 
ADVERSE EFFECTS: 
Hypersensitivity reactions , Hypotension ,bradycardia, nausea, vomiting, 
fever, paresthesia,  headache, pruritus , urinary retention, rigors and back pain. 
Less common side effects : CNS toxicity, cardiac toxicity.                                                            
DRUG INTERACTIONS 
· Duration and intensity of block will not be altered by adding adrenaline. 
· Additive effects with other local anaesthetic 
· When used with potent enzyme inhibitors like fluvoxamine, verapamil 
will prolong the half life. 
· When used with ketaconazole reduces the plasma clearance by 15 %. 
EPIDURAL ADMINISTRATION 
Ropivacaine is less potent than bupivacaine in equal volume of doses of 
similar concentration given  epidurally. Ropivacaine potency in relation to 
potency of bupivacaine is ½ with regard to motor blockade and 2/3rd with regard 
to sensory blockade . 
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PHARMACOLOGY OF DEXMEDETOMIDINE(20) 
Dexmedetomidine hydrochloride 
Dexmedetomidine is  a highly selective alpha-2-adrenoceptor agonist with 
sedative, anxiolytic,  and  analgesic properties. Dexmedetomidine is more 
selective for α2 receptors with 1600 times greater affinity  than  α₁ receptor. In 
1999, U.S. Food and Drug Administration (FDA) approved  dexemedetomidine 
for  first time use in adults. It  was used   as a short term sedative agent in ICU 
for adult patients on mechanical ventilator .α2-agonists were used in treating 
hypertensive patients and for withdrawl  symptoms of alcohol and drug abusers. 
Now it is widely used as sedative, adjunct analgesia for various diagnostic 
procedures. 
Chemical formula    :  
(+)-4-(d)-[1-(2,3-dimethylphenyl)ethyl]-1H-imidazole monohydrochloride,  
an imidazole derivative 
STRUCTURAL FORMULA 
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Physio Chemical Charecteristics : 
Dexmedetomidine hydrochloride is the d-enantiomer of medetomidine 
molecular weight  : 236.7 
empirical formula : C14H16N2.HCL 
Pharmacokinetics of dexmedetomidine :  
Administration : 
The most common route of dexmedetomidine administration is 
intravenous, other routes are intranasal, buccal, peroral, transdermal, and 
intramuscular, epidural and  intrathecal   administration.   
The level of bioavailability is highest for the buccal route (82%), 
intramuscular(73% ) and transdermal routes ( 51%)  
Distribution: 
Dexmedetomidine has a rapid distribution phase, with a distribution t1/2 
of approximately six minutes.The steady-state volume of distribution is  about  
97 ± 29 liters. It binds to  alpha- glycoprotein and serum albumin, with an 
average protein binding  ability of 94%.  Protein-binding ability of drug  doesnot 
varies with sex. Patients with decompensated liver disease have decreased 
binding to plasma proteins when  compared to healthy subjects. There is no 
reported significant drug-drug interaction due to changes in protein-bounding 
ability.  In vitro , combination with different common highly protein-bound 
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drugs including fentanyl, ketorolac, theophylline, lidocaine, and warfarin showed 
no significant drug interactions .  
Metabolism: 
Metabolism  of  dexmedetomidine is mainly occurs  by hepatic  
biotransformation  with very little unchanged dexmedetomidine excreted in the 
urine and feces. Hepatic  biotransformation involves both direct glucuronidation 
and cytochrome P450  mediated metabolism.  The major metabolic pathways of 
dexmedetomidine  include   
1) Direct N-glucuronidation to generate  inactive metabolites;  
2) Aliphatic hydroxylation (mediated primarily by CYP2A6) of  
dexmedetomidine to generate 3-hydroxy-dexmedetomidine, the 
glucuronide of 3-hydroxy-dexmedetomidine and  
3-carboxydexmedetomidine;  
3) N methylation of dexmedetomidine to generate 3-hydroxy N-methyl-
dexmedetomidine, 3-carboxy N-methyl-dexmedetomidine, and 
dexmedetomidine- N-methyl O-glucuronide.  
It  has been shown to have a mild inhibitory effect on CYP2D6-dependent 
dextromethorphan O-demethylase activity.  
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Elimination: 
Terminal elimination half-life (t½) - two hours 
Clearance  rate - 39 ± 10L/hr  
Ninety-five  percent of the drug is excreted as metabolites in urine   
(Among metabolities - 34% products of N-glucuronidation; 14% products of 
aliphatic hydroxylation, 18% products of N-methylation, 28% unidentified) 
Four percent in the feces.  
Unchanged dexmedetomidine is  not detected in the urine. Approximately 
85% of the metabolites of dexmedetomidine  are excreted  in the urine within 24 
hours after the infusion. 
Paediatric patients: 
Pharmacokinetics of dexmedetomidine in  the paediatric patients  is 
similar to those  that found in adults. 
Volume of distribution (Vd) 1.5-2.2l/kg,  
Clearance rate (Cl) 0.56-1l/kg/hr 
Terminal t½ 1.6-2.7 hours.  
However, the CL in neonates was just 18.19 l/hr/70 kg. This was attributed to 
immature enzymatic pathways.  
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Age and Gender:  
Pharmacokinetics of dexmedetomidine , there is no variation seen in both 
the sexes and in age groups.  
Hepatic impairement : 
Patients with severe hepatic failure showed a significantly increased 
Volume of distribution,and decreased terminal half-life and clearance values of 
dexmedetomidine compared with age-matched controls;  In patients with hepatic 
insufficiency pharmacokinetics of dexmedetomidine were markedly affected. 
Hence dose adjustment must needed  in patients with hepatic  insufficiency.  
Renal Impairement   
Pharmacokinetics of dexmedetomidine did not differ  in subjects with 
normal renal function, and in those with severe renal impairment only the 
excretion of metabolites are  affected.  
Pharmacodynamics of dexmedetomidine 
1) Cardiovascular system: 
Dexmedetomidine can produce either hypo- or hypertension. At lower 
doses, sympatholysis occurs  which is mediated by the alpha-2A-adrenergic  
receptor subtype. There are several  mechanisms for this activity, including the 
inhibition of the firing of the locus coeruleus (the pivotal noradrenergic replay 
nucleus in the brain stem) and inhibition of nerepinephrine release at the neuro-
effector junction.  
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Central and peripheral sympatholytic  effects of alpha-2 adrenoceptor 
stimulation may be augmented further by the inhibition of  ganglionic 
transmission. The inhibition of sympathetic activity produces hypotension, 
bradycardia and sedation . 
At higher doses, the hypertensive action dominates via the  activation of 
alpha-2B adrenoceptors, which are located on the smooth muscle  cells in the 
resistance vessels.  
2)  Respiratory system : 
Dexmedetomidine causes a slight increase in PaCO2.  In addition, 
dexmedetomidine does not  produce significant respiratory depression or 
decrease arterial oxygen saturation.   
Several prospective studies have found minimal or no change in 
respiratory function during the administration of  dexmedetomidine .  
3)  Central nervous system : 
Sedation: 
The locus coeruleus which is a  predominant noradrenergic nucleus in the 
brainstem, responsible for  the sedative and hypnotic response to alpha-2 
agonists by reducing the firing of neurons.Dexmedetomidine induces sedation 
that is qualitatively different from that produced by other commonly used 
sedative agents.Despite being deeply sedated, on arousal stimulus  subjects were 
able to perform a complex task without loss of accuracy. 
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       Dexmedetomidine produces profound anxiolysis in surgical patients by 
decreasing the sympathetic outflow. 
4)  Analgesia  : 
The primary site of   action is on spinal cord.  It  produces  analgesic 
effect   by  inhibition of  the release of substance P from the dorsal horn of the 
spinal cord result.  
5)  Gastric emptying : 
Dexmedetomidine delays gastric emptying and gastrointestinal transit, but 
the degree of this effect is trivial when compared with the effect of morphine  
6) Salivation and secretion levels are also reduced. 
7)  Eyes : 
Intraocular pressure is reduced  and  produces  mydriasis.  
Dexmedetomidine is a highly selective alpha-2-adrenergic receptor 
agonist. Adrenergic receptors  are classified as  alpha or beta adrenoceptors 
which mediate the effects of catecholamines .Alpha receptors are located pre-and  
post-,  even extrasynaptically. Alpha receptors are subclassified as alpha-1 and 
alpha-2 adrenoceptors. Three alpha-2-adrenoceptor agonist subtypes, alpha-2A, 
alpha-2B  and alpha-2C, have  been identified by radioligand binding studies and  
which has subsequently confirmed by genetic cloning.  
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            Alpha-2 adrenoceptors are cell membrane receptors which is composed 
of a single polypeptide chain.  Alpha-2 adrenoceptors are part of the G protein-
coupled receptor  superfamily. Alpha-2 adrenoceptors subtypes are only 50% 
conserved at the amino acid level, but they exhibit 72-75% identity in their 
membrane-spanning hydrophobic domains, which  arranged as alpha helices,  are 
the site for ligand binding.This arrangement of amino acids within these 
segments determines ligand specificity .  
Physiological functions of α 2 receptors 
α2a – Presynaptic feedback inhibition of norepinephrine release  
           Analgesia 
           Sedation 
           Inhibition of epileptic seizures 
           Hypotension 
           α 2b – Hypertension   ( at higher doses ) 
                     Analgesic effect of nitrous oxide 
            Placental angiogenesis       
           α 2c –Feedback inhibition of adrenal catecholamine release 
                     Modulation of behaviour 
                     Analgesic effect of moxonidine 
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MECANISM OF ACTION: 
1) Activate inhibitory action of G proteins which result into decrease in 
cyclic  AMP  
2) Activate G proteins which directly act on membrane bound ion channels, 
mainly on  potassium channels  
3) By inhibiting the release  of   noradrenaline within neuronal tissue, 
activate nitric oxide and cyclic GMP pathway  
Action  on the dorsal motor complex of medulla , causing bradycardia and  
hypotension. Action on  locus coeruleus leading to sedation and analgesia . 
Alpha 2 receptors are G protein –coupled receptors in the transmembrane region 
of the central and peripheral nervous system selectively at autonomic ganglion of 
presynaptic and postsynaptic region. Nor epinephrine and clonidine acts on these 
receptors inhibit the enzymes adenyl cyclase and phospholipase C resulting in 
the inhibition of calcium ion entry and facilitation of opening potassium ion 
channels outwards that results in hyperpolarization.  
Presynaptic activation  of α 2 adrenergic receptors, in the  sympathetic 
nerve endings  and  in the  nor adrenergic neurons, inhibition of  norepinephrine 
release occurs. In  central  nervous   system, this  leading  to inhibition of 
sympathetic activity, resulting in sedation, hypotension and bradycardia. But at 
higher doses it produces  hypertension  through receptor activation  present in 
smooth muscle cells of the resistance vessels. Hypnosis occurs  by action on α2 
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receptors of locus coeruleus,analgesia mediated by action on  α 2 receptors in 
spinal cord. α2 agonists like clonidine and  dexmedetomidine with Imidazoline 
ring which  interact with imidazoline receptors  (21).   
Drug Interactions : 
No evidence of cytochrome P450 mediated drug interactions.  Concurrent  
administration of anaesthestic, sedatives, hypnotics or opioids may lead to 
enhancement of their effect and  may need reduction of dose. 
Pregnancy, Labour and Lactation : 
There were no adequate and well controlled trails, hence should be used 
with caution  
ADVERSE  EFFECTS : 
Most frequently observed side effects are hypo or hypertension, dry 
mouth, bradycardia and nausea. Other side effects are fever,arrhythmias,AV  
block,extra systoles,pulmonary  oedema,dizziness,headache etc.  
ALPHA 2 ANTAGONIST(22)  : 
Atipamezole  : 
Atipamezole is a selective α 2 adrenoceptor antagonist. Intravenous 
atipamezole reverses the sedation and sympatholysis effect of  dexmedetomidine    
in  the dose dependent manner in titrated doses. 
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PHARMACOLOGY OF FENTANYL (19, 20) 
Fentanyl citrate : 
Fentanyl  is a synthetic opioid agonist , phenyl piperidine –derivative of 
that is structurally related to meperidine. Its analgesic efficacy is 75 – 125 times 
more potent than morphine. 
CHEMICAL STRUCTURE 
 Phenylpiperidine derivative of the 4-anilopiperidine series  
STRUCTURAL FORMULA 
 
PHYSIOCHEMICAL PROPERTIES 
Commercially available as fentanyl citrate, available as an aqueous 
solution without preservatives. 
Molecular weight     :  528.29 
pKa                             :  8.4 
Octanol / water partition coefficient : 955 
 % bound to plasma proteins                  : 84 
 Potency       : 75 – 125 times more 
potent than morphine   
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PHARMACOKINETICS:  
ABSORPTION  
Injection of Opioids in the epidural space result into epidural fat uptake, 
then into systemic absorption or into the cerebrospinal fluid by diffusion across 
the dura. Penetration of the dura is depends on  lipid solubility. Fentanyl , 
sufentanil are more    lipid  soluble than  morphine. Intravenous  administration 
of a  single dose of fentanyl has a more rapid onset  of action and  shorter 
duration of action than morphine 
METABOLISM 
It is primarily metabolized in liver by N-dealkylation and hydroxylation 
producing hydroxyproprionyl fentanyl,and hydroxyproprionyl norfentanyl, nor-
fentanyl.  
The elimination half-life: 3.1-6.6 hours. 
The clearance rate: 1530 ml / minute.  
Context sensitive half time after 4 hours of infusion: 260 minutes. 
The effect-site equilibration time :  6.4 minutes  
The volume of distribution:  335 litres. 
ELIMINATION  
The metabolite is mainly  excreted via kidneys and metabolite can  be 
detected in urine upto 48 hours.  
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PHARMACODYNAMICS 
Central nervous system:  
It  decreases  intracranial pressure and CMRO2 . 
Muscle rigidity can occur due to increase in muscle tone . 
Cardiovascular system:  
Attenuates  the hemodynamic response to laryngoscopy and endotracheal 
intubation by reducing the  sympathetic tone. Reduction in blood pressure can 
occur due to inhibition of neurotransmitter (dopamine, nor epinephrine, 
substance P). stimulation of the central vagal nucleus cause reduction in  
heart rate . 
Respiratory system:  
Dose dependent depression of ventilatory response to CO2occurs. It 
depresses the  airway  reflexes, eliminates  autonomic and somatic response to 
tracheal intubation. 
Endocrine effects:       
Prevents  increase in stress hormone such as  plasma catecholamines , 
antidiuretic hormone, renin, aldosterone, growth hormone and cortisol 
concentrations. 
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Gastrointestinal system:  
Stimulation of Chemoreceptor trigger zone in area postrema of medulla is  
the important cause for nausea and vomiting. It also relaxes the lower esophageal 
sphincter and delays gastric emptying.  
Renal system:  
no significant effects occurs 
MECHANISM OF ACTION 
Fentanyl is a mu-receptor agonists,  opioid like activity seen  in the central 
nervous system mainly in the brainstem and spinal cord and outside the central 
nervous system in peripheral tissues. 
After placement of opioid epidurally, diffusion of the drug across the dura 
occurs which  gain access to mu opioid receptors in the substantia gelatinosa of 
the spinal cord. 
Due to opioid receptor activation,  presynaptic inhibition of 
neurotransmitter (acetylcholine, dopamine, nor epinephrine, substance P) release 
occurs which decreases the neurotransmission .  
After epidural administration of opioid , it  diffuses across the dura and 
reaches CSF   or  absorption of the opioid through the epidural fat.   
The extent of dural diffusion is  mainly depends  on lipid solubility, and 
also depends on  molecular weight . Considerable CSF opioids concentrations  
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are produced  after  epidural administration and peak concentration of fentanyl in 
csf seen in 20 minutes. The high lipid solubility favours shorter duration of 
action and greater systemic absorption.  Diffusion of drug  into  the epidural 
veins is the major route of clearance. 
 
Epidural Opioid. In the spinal cord, nonionized hydrophilic drug (blue 
circles) and the ionized hydrophilic drug (red triangles) at the site of the spinal 
opioid receptor (purple receptors) is shown, as well as nonspecific lipid-binding 
sites (green receptors) is also shown . Diffusion of drug  into the epidural veins  
as illustrated in the left portion of the image. 
DOSAGE AND ADMINISTRATION 
Analgesic dose : 1-2 μg/kg iv 
Total intravenous anaesthesia : Loading dose : 4-20μg/kg iv 
        Maintenance dose :  2-10μg / kg / hr iv 
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Blunts the intubation response : 2-20μg/kg  iv , along with inhalational 
agents. Augmentation of effects of local anesthetics in spinal and epidural 
analgesia at dose of 10-25µg and 25-100µg  respectively. 
SIDE EFFECTS :  
Nausea, vomiting, pruritis, urinary retention, muscular rigidity of the 
chest wall and   also can produces  dose dependent respiratory depression. 
Drug interactions:  
Opioid- benzodiazepine synergism  seen  with  respect to hypnosis and 
depression of ventilation.  Analgesic concentrations of fentanyl  along with 
midazolam potentiates midazolam  the effect by synergistic action  and  also  
decrease the dose requirements of propofol. 
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REVIEW OF LITERATURE 
1. Sukhminder jit singh bajwa, et al  (2011)(23) had conducted 
“Comparative evaluation of dexmedetomidine and fentanyl for epidural 
analgesia in lower limb orthopedic surgeries”  They had randomly allocated  100 
patients into two groups , Inj.  0.75% Ropivacaine 15 ml  was administered 
epidurally in both the groups  with  addition of  dexmedetomidine1 μg/kg in RD 
group and of fentanyl 1 μg/kg in RF group. They had observed time taken to 
reach sensory  of  T10, maximum sensory  level, time taken to achieve complete 
motor blockade and time for  first rescue analgesia . They had found that onset of 
sensory level  at T10 was(7.12±2.44 vs 9.14±2.94) (P=0.016) and attainment  of 
complete motor blockade (18.16±4.52 vs 22.98±4.78) (P=0.033) was 
significantly earlier in the RD group. Postoperative analgesia was prolonged 
significantly in the RD group (366.62±24.42 vs 242.16±23.86 )  and with  low 
dose consumption of local anaesthetic ropivacaine (76.82±14.28 vs 
104.35±18.96) for epidural top‑ups  postoperatively. Sedation scores (P<0.001) 
were  significant in the RD group. They had concluded dexmedetomidine was  a 
better alternative to  fentanyl as an epidural adjuvant.  
2. Rashpal Singh Gill at al ( 2016) (24) conducted a  prospective, 
randomized  study “Comparative evaluation of addition of fentanyl and 
dexmedetomidine to ropivacaine for epidural anaesthesia & analgesia in lower 
abdominal and lower limb orthopedic surgeries” . In this study ,group RD 
received  Inj.  0.75 % Ropivacaine 15 ml with  1 μg/kg of dexmedetomidine 
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epidurally  and group RF received Inj.  0.75 % Ropivacaine 15 ml with  1 μg/kg 
of fentanyl  epidurally . . They had  found that onset of sensory level  at T10 
was(9.62±1.32 vs 11.94±1.07) (P=0.040) and  time for complete motor blockade 
(19.86±1.66 vs 27.72±1.21) (P=0.003) was significantly earlier in the RD group 
than RF group . Postoperative analgesia was prolonged significantly in the RD 
group (358.3±7.864) and with  low dose consumption of local anaesthetic 
ropivacaine postoperatively (63.68±9.958 vs 85.96±13.988) (P<0.001) . They 
concluded  that   epidural dexmedetomidine seems to be a better additive  to 
epidural ropivacaine when compared to epidural fentanyl . 
3. Kumkum Gupta et al (2016)(25) conducted “Epidural 0.5% 
levobupivacaine with dexmedetomidine versus fentanyl for vaginal 
hysterectomy: A prospective study”. In this study ,60 patients were double 
blindly randomized into two  groups, patient  received epidural 15 ml of 0.5% 
levobupivacaine l either with of 25 μg dexmedetomidine (Group LD) or 50 μg 
fentanyl (Group LF). They observed  onset  of sensory level  at T10, maximum 
sensory  levels , sedation,  duration of analgesia. They had found result that the 
onset of sensory analgesia at T10 (7.25 ± 2.3 versus 9.27 ± 2.79 min ) and time 
to attain  complete motor blockade (19.27 ± 4.7 versus 22.78 ± 5.57 min) was 
significantly earlier in  LD Group. Sedation score  and post operative analgesia 
(187.7±6.9 versus 146.7±8.3) was statistically significant in  LD group.  They  
concluded  that  the  dexmedetomidine was better adjunct  to the epidural 
anaesthesia when compared with  fentanyl .  
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4. Sarabjit Kaur,et al(26) ( 2014)  conducted  a prospective  study to 
compare  analgesic effects of epidurally administered ropivacaine and  
dexmedetomidine when compared with  plain ropivacaine  in undergoing lower 
limb surgeries . They randomized 100 patients  into two groups as  group A and 
B  . Group A (n = 50) patients  received plain  ropivacaine in the epidural and 
Group B (n = 50) patients received  dexmedetomidine as adjuvant to epidural 
ropivacaine . They had  compared  the two groups with respect to  time to onset 
of sensory level  at T10, time to maximum sensory and motor block  and time of 
rescue analgesia . They had  observed that significant difference was seen  in 
relation to the duration  of sensory block  prolonged   in group group B (535.18 ± 
19.85 min) than group A (375.20 ± 15.97 min ),p=0.000 and similarly duration 
of motor block  prolonged   in group B( 385.92 ± 17.71 min)  than group A  
(259.80 ± 15.48)   p=0.000 ,  prolonged duration of post-operative analgesia seen 
in group B  (312.64 ± 16.21 min versus  496.56 ± 16.08 min in Group B ) and  
low doses of rescue analgesia  needed in Group B  as compared to Group A .  
Better sedation score was seen in Group B . Finally,  they had  concluded that 
epidural dexmedetomidine as  a better  adjuvant to Ropivacaine when compared 
to plain Ropivacaine. 
5. Bhawana Rastogi et al ( 2015) (27) “ Dexmedetomidine as an adjuvant to 
epidural 0.75% ropivacaine in patients undergoing infraumbilical surgery: a 
clinical study” .  They had randomized study  population  into group A and B( 40 
patients in each group)  .  inj . 0.75 % ropivacaine alone was given in the 
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epidural in Group A whereas inj 0.75 % ropivacine with  dexmedetomidine 0.6 
µg/kg was given in the epidural in group B . They had found that onset of 
sensory block  was early in group B  and achieving  complete motor block  was 
significantly earlier in the ropivacaine with dexmedetomidine group. 
Postoperative analgesia was  also prolonged significantly in the ropivacaine with 
 group B. Dexmedetomidine is effective adjuvant to the epidural ropivacaine  as 
it prolongs duration of  sensory and motor block with adequate sedation level  
and  with minimal side effects. 
6. Manjunath Thimmappa co workers (2014) (28) conducted a prospective 
study  in 90 patients of ASA1&2 underwent lower abdominal  and lower  limb 
surgeries under epidural anaesthesia  for comparision of epidural ropivacaine 
alone and epidural ropivacaine with alpha agonists . 30 patients in each group 
were randomly allocated into 3 groups R,RC,RD  administered 19ml of 0.75% 
ropivacaine with 1ml of normal saline, 19ml of  0.75% ropivacaine with 
75microgram(mcg) clonidine ,19ml of 0.75% ropivacaine with 75 mcg 
dexmedetomidine respectively. Sensory onset ,hemodynamic parameters, 
sedation , duration of analgesia were compared  in all the groups and they had  
reported that onset of blockade is faster when alpha agonists used as adjunct .  
Time for rescue analgesia was longer in “RD” group. Group RC had mild 
sedation, group RD had moderate sedation. and associated with side effects like 
bradycardia and hypotension in both RC and RD groups was a major problem in 
hemodynamic profile.They had concluded  that  using  alpha 2 agonists as 
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adjunct to epidural ropivacaine  fastens the onset of action,better analgesia  was 
seen with dexmedetomidine,  duration of analgesia was prolonged with 
dexmedetomidine. 
7. MS Saravana babu et al(2014) (29) conducted “ A comparative study in 
the post-operative spine surgeries: Epidural ropivacaine with dexmedetomidine 
and ropivacaine with clonidine for post-operative analgesia” patients allocated 
into three groups , 0.2% ropivacaine with  dexmedetomidine(group RD) or  0.2% 
ropivacaine clonidine (group RC). After  statistical analysis , they  had  obtained 
the following results as adding of dexmedetomidine to epidural  ropivacaine  
resulted in  earlier onset (7.33±1.76 min) of analgesia as compared with 
clonidine (8.40±1.61 min). The duration of  analgesia was also prolonged in 
dexmedetomidine group (407.00±47.06 min) compared to clonidine group 
(345.01±35.02). The requirement of  IV rescue analgesics in both groups were 
nil . The mean VAS score was higher in the clonidine group(group RC) at each 
time interval.They have  concluded  that   the epidural route of analgesia was 
adequate  in spine surgeries.Dexmedetomidine is a better neuraxial adjuvant to 
epidural ropivacaine when compared with clonidine for providing early onset  of 
analgesia and prolonged post‑operative analgesia and stable haemodynamics 
prolife .  
8. Salgado PF et al (2008)(30)  conducted a randomized prospective  control 
study in 40 patients who underwent  varicose vein, hernia repair surgeries under 
epidural anaesthesia. They did comparative study between patients receiving   
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0.75% ropivacaine (20 ml) and 0.75% ropivacaine (20 ml) added to 
dexmedetomidine 1µg/kg. They had observed that addition of  dexmedetomidine 
did  not affect the onset time or upper level of anaesthesia .However sensory and 
motor block duration   was prolonged, post operative analgesia was longer  and 
more intense motor block. There was no difference in incidence of hypotension 
and bradycardia.  They concluded that there is  existence   synergism between 
epidural dexmedetomidine and ropivacaine.  
9. Manal M.Kamal et al (2014) (31) had  conducted prospective study on 
patients undergoing abdominal surgery they had randomly divided 60  
patients  into two groups, group I levobupivacaine morphine group (LM),  
group II: levobupivacaine dexmedetomidine group (LD) . They had observed  
onset, duration of sensory and motor blocks, abdominal muscle relaxation, and 
side effects .  They had obtained a result after statistical analysis  that the  time to 
reach total  motor block was  significantly shorter in the LM group than the LD 
group. There were no significant differences between the two groups in relsation 
to onset of sensory block,  sedation score  and abdominal muscle relaxation. 
16.6% of  patients in the LM group suffered from pruritis and  20% of   patient in 
the LD group had dry mouth  as side effect seen .They had concluded that 
Dexmedetomidine is a good  adjuvant to levobupivacaine as alternative to 
morphine in epidural anesthesia in major abdominal surgeries.  
10. Dr. Mahendra Singh et al (2016) (32) “ Randomized, prospective and 
comparative study between ropivacaine and ropivacaine with dexmedetomidine 
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in Epidural anesthesia for  patient undergoing abdominal hysterectomy”. Group I 
and II  received epidural 17ml of ropivacaine 0.75 %  and  epidural  17 ml of 
Ropivacaine 0.75 %  with dexmedetomidine 1.5 ug/kg respectively . Sensory , 
motor and hemodynamic profile between two groups were observed and 
statistical analysis done .  They had concluded that no  statistical significant 
difference was found between the two  groups in sensory and motor profile . 
Hemodynamic stability was seems to be  better with dexmedetomidine. Rescue 
analgesic dose  requirement was reduced in dexmedetomidine group. 
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MATERIALS  AND  METHODS 
The study  was  conducted at chengalpattu medical college between 2015-
2016. After obtaining ethical committee approval,60 ASA І- ІІ patients 
undergoing  elective lower  limb orthopaedic  surgeries were  randomly allotted 
into two groups  
Study design : A Prospective randomized double-blinded study  
Sample size : 60 patients were selected and randomly divided into two  
groups  A and B. 
Group A (n=30) received  15ml of 0.5 % Ropivacaine   with  1 μg/kg of  
dexmedetomidine  epidurally    
Group B (n = 30 ) received   15ml of  0.5 % Ropivacaine  with  1 μg/kg of  
fentanyl  epidurally  
INCLUSION CRITERIA: 
} ASA grade I  & II status. 
} 18-60 years of age. 
} Patients giving informed written consent. 
} Patients scheduled to undergoing elective  lower limb orthopedic  surgery 
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EXCLUSION CRITERIA 
} Age < 18 years and > 60 years 
} ASA class > II 
} Patients refusal 
} Patients with hypersensitivity to local anaesthetic 
} Any contraindication to spinal or epidural anaesthesia  
} Patients taking alpha-2 adrenergic agonists, tricyclic antidepressants, any 
antipsychotic drugs, antiarrhythmics, betablockers, anticoagulants and  
opioids.  
ANTHROPOMETRY MEASUREMENTS: (33) 
As the patients  were undergoing  lower limb orthopedic  surgery, patients 
were  immobile and thus measurements of body weight was impossible . Hence a 
nomogram was used to calculate the body weight from the basic measurements 
like height, waist circumference, and hip circumference.  
BODY WEIGHT NOMOGRAM FOR MALE (A) AND FEMALE (B) 
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MATERIALS USED  : 
1. 17 G Tuohy needle 
2.  19 G epidural catheter 
3. 1ml, 2 ml,5 ml,20 ml sterile syringes 
4.  Hypodermic needles – 18G & 26G 
5.   Sterile Bowl, Sponge holding forceps, gauze, betadine solution. 
6.  Sterile gown, Gloves 
7.  Local anaesthetic solution – 2  % Lignocaine with adrenaline 1 : 200000 
and 2%  lignocaine  
8. 0.5% Ropivacaine 20 ml ampoule, Fentanyl -100µg 2ml  ampoule, 
dexmedetomedine 100 µg 1ml ampoule. 
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9. Emergency drugs like Inj. Adrenaline, Inj. Atropine, Inj.Ephedrine, 
Inj.Dopamine, Inj.Thiopentone, Inj.Succinylcholine.  
10.  Emergency kit with working laryngoscope, cuffed endotracheal  tubes of 
appropriate size, airway, suction apparatus with suction catheter. 
11.  Multipara  monitor for  monitoring of pulse rate, non-invasive blood 
pressure, electrocardiogram ,oxygen saturation. 
METHODOLOGY    
Preoperative  preparation : 
} Patients who satisfy the inclusion criteria were selected  
} Informed consent was obtained from  the patients  .   
} Preoperative evaluation including detailed medical and surgical  history,  
drug  intake history ,clinical evaluation, airway assessment ,investigations  
were done  
} Visual Analogue Scale (VAS) was explained in detail to the patients in 
the  preoperative  period  . 
} Intradermal test dose was given with 0.1ml  of 2% lignocaine . 
} Patient was shifted inside the operation threatre , IV line secured with 18G 
cannula,  premedication with injection raniditine 50mg iv, injection 
glycopyrrolate 0. 2 mg iv given .  
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} Patients were connected to multipara monitor showing electrocardiogram, 
pulse rate, non invasive blood pressure  and oxygen saturation  and basal 
readings were recorded. 
}  All patients  received ringer’s lactate solution 10ml/kg as preloading 
solution . 
} Under strict aseptic precautions, Lumbar epidural anesthesia was 
performed using 17G Touhy needle with patients in the sitting position in 
L3-L4 interspace  and location of epidural space was confirmed by loss of 
resistance technique. Epidural catheter  (19 G ) advanced cephalad  3–5 
cm into the epidural space 
} A test dose of 3 ml of 2 % lignocaine with adrenaline was administered 
into epidural space and thereafter epidural catheter was secured and 
patients were placed  supine. 
 
} The anaesthetist  who prepared the drug combination did not participate in 
the monitoring or assessment  of the patient.The person who performed 
the epidural  block as well as monitoring  was blinded from  which  group  
the  patient belongs.  
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} Preparation of   the drug combination : 15 ml of 0.5% ropivacaine was 
taken  in 20 ml syringe in which 1 μg/kg of  dexemedetomidine or 
fentanyl  added using 1ml syringe. 
} The following solutions were randomly administered: 15 ml of 0.5% 
ropivacaine with 1 μg/kg of dexemedetomidine in group A(n=30) and 1 
μg/kg of fentanyl in group B (n=30) . 
}  Supplemental oxygen provided during surgery. 
The following parameters were observed following the block  
Time of onset of analgesia at T10,  
Maximum sensory level achieved , 
Time taken for complete  motor blockade, 
Sedation score 
Total duration of analgesia,  
Time  of first rescue analgesia  
Haemodynamic parameters  
Side effects  
Time of onset of analgesia at T10 
Time interval between the end of administration of drug  and the onset of 
sensory block   at T10  level will be evaluated using midline loss of cold 
sensation  every minute till complete sensory block at T10 at which point surgery 
will be proceeded. 
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Maximum sensory level achieved :  
Assessed by loss of cold sensation  with cotton soaked in isopropyl 
alcohol ( spirit ) 
Time to complete  motor blockade:  
Degree of motor block  was assessed after complete sensory block was 
achieved   at T10 level using modified Bromage scale for every 5 minutes  
0 = No block  
1 = Inability to raise extended leg 
2 = inability to flex the knee 
3 = inability to flex ankle and foot 
Sedation score 
Sedation scores was  recorded  every 15 minutes till 60 min  and then 
every hourly upto 180 minutes. Level of sedation will be  assessed using 
observer ‘s assessment of alertness/sedation scale . 
1 = alert and wide awake 
2 = arousable to verbal commands 
3 = arousable to gentle tactile stimulation 
4 = arosable to vigorous shaking 
5 = unarousable 
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Total duration of analgesia:  
Time interval from the completion of anaesthesia  to the time when the 
patient complains of pain 
Time of first  rescue analgesia   
Time interval from the completion of anaesthesia  to the time the patient 
experiences pain of verbral analogue score > 4 . epidural tramadol 50 mg was 
given as rescue analgesia  ,when patient experiences pain of  verbal analogue 
score  >4. 
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Hemodynamic parameters 
Baseline pulse rate , oxygen saturation, noninvasive blood pressure were  
recorded. Above mentioned  parameters were  monitored continuously and 
recordings were  made every 5 minutes until 30 minutes and at 15 min interval  
upto 90 minutes and finally at 30 minute upto 180 minutes. Incidence of 
bradycardia (heart rate<60beats per minute) was treated with 0.6mg of injection 
atropine and hypotension (20% reduction in baseline  blood pressure ) was 
treated with injection ephedrine 6 mg i.v bolus . 
SIDE EFFECTS 
During surgical procedure side effects like nausea, vomiting, anxiety ,dry 
mouth, dizziness, headache, pruritis, shivering and respiratory depression were 
recorded. 
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OBSERVATION AND RESULTS 
The following observations were made and datas were collected. 
· Time of onset of analgesia at T10, 
· Maximum sensory level achieved, 
· Time taken for complete motor blockade, 
· Sedation score 
· Total duration of analgesia, 
· Time of first rescue analgesia  
· Haemodynamic parameters  
· Side effects  
STATISTICAL ANALYSIS 
Appropriate statistical analysis of data was done using following tests 
1. Two sided independent Student t testand Mann-Whitney U test for parametric 
data. 
2. Chi-square test for non-parametric data.  
P<0.05 was considered as statistically significant. 
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DEMOGRAPHIC DATA 
Group A and B were comparable with regard to their age, weight, 
sex.There is no statistically significant difference seen between two groups in the 
demographic profile. 
AGE(student’s t test)  
Group No of cases Mean ± S.D (years) P value 
Group A 30 38.53±12.467 
0.139 
Group B 30 43.4±12.689 
 
The mean age in years was 38.53±12.467 (years) in group A and 
43.4±12.689 (years) in group B.There was statistically no significant difference 
between two groups (p>0.05). 
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SEX   DISTRIBUTION  
Group Male Female Total 
Group A 25 5 30 
Group B 26 4 30 
TOTAL 51 9 60 
 
There was statistically no significant difference in sex distribution 
between   two groups (p>0.05). 
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WEIGHT(Student’s   t test) 
 No of cases Mean±S.D(kg) P value 
Group A 30 61.93 ±10.866 
0.821 
Group B 30 62.53± 9.573 
 
The mean weight was 61.93± 10.866 (Kg) in group A and  
62.53± 9.573(Kg) in group B. There is no statistically significant difference 
between both groups. 
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TYPES OF SURGERY: 
NAME OF SURGERY Group A (No.of cases) 
Group B 
(No.of cases) 
ARTHROSCOPIC LIGAMENT REPAIR 1 3 
EXTERNAL FIXATION OF TIBIA 1 0 
FEMUR NAILING 10 10 
FEMUR PLATING 0 1 
HEMIARTHROPLASTY 1 5 
TIBIAL NAILING 15 9 
TOTAL HIP REPLACEMENT 1 1 
TOTAL KNEE REPLACEMENT 1 1 
 
No significant difference among both groups 
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ONSET OF SENSORY BLOCK AT T 10LEVEL 
The mean time for onset of sensory block is 3.87±0.681 (minutes)in group 
A and6.03±1.47 (minutes) in group B. There was significant difference among 
two groups in the timefor onset of sensory block at T 10 level. (p<0.05). 
Group Mean (min) S.D P value 
Group A 3.87 0.681 
0.0001 
Group B 6.03 1.47 
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MAXIMUM SENSORY LEVEL ACHIEVED                           
MAXIMUM SENSORY 
LEVEL ACHIEVED Group A Group B Total 
Chi 
square p value 
T10 0 3 3 
21.3 0.0001 
T8 5 19 24 
T6 20 8 28 
T4 5 0 5 
Total 30 30 60 
 
None of patient in group B achieved T 4 level of sensory block, there was 
statistical significant difference seen in maximum sensory level achieved.  
(P< 0.05) by chi square. 
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TIME TAKEN FOR  COMPLETE MOTOR BLOCK 
Group Mean (min) S.D P value 
Group A 19 3.151 
0.0001 
Group B 23.37 2.58 
 
The mean time for complete motor block was 19±3.151 (minutes)in group 
A and 23.37±2.58 (minutes) in group B. There was significantdifference among 
two groups in time for complete motor block. (p<0.05). 
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SEDATION SCORE (Mann-Whitney U test) 
Time Sedation Score Group A Group B 
0 Min 1 30 30 
15 Mins 1 29 28 
  2 1 2 
30 Mins 1 13 22 
  2 16 8 
  3 1 
45 Mins 1 10 23 
  2 17 7 
  3 3 
60 Mins 1 14 27 
  2 13 3 
  3 3 
120Mins 1 26 30 
  2 4 
180Mins 1 30 30 
 
 
There was significant difference among two groups in sedation score. (p<0.05) 
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TOTAL DURATION OF ANALGESIA 
Group Mean (min) S.D P value 
Group A 335.83 41.316 
0.0001 
Group B 285.17 25.914 
 
The mean time of total duration of sensory block was 335.83±41.316 
(minutes) in group A and285.37±25.914 (minutes) in group B. There was 
significant difference among two groups in total duration of sensory block. 
(p<0.05). 
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TIME OF FIRST RESCUE ANALGESIA 
Group Mean (min) S.D P value 
Group A 373.67 45.636 
0.0001 
Group B 314.1 28.403 
 
The mean time for first rescue analgesia was 373.67±45.636 (minutes) in 
group A and314.1±28.403 (minutes) in group B. There was significant difference 
among two groups in time for first rescue analgesia. (p<0.05) 
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HAEMODYNAMIC PARAMETERS: 
COMPARISON OF HEART RATE (Student’s t test) 
The following table shows the heart rate variations which showed 
statistical difference in both groups (p<0.05). 
TIME 
GROUP A GROUP B 
p value 
MEAN SD MEAN SD 
Baseline 82.73 6.486 83.27 5.93 0.741 
0 min 82.47 6.616 85.53 6.426 0.074 
5 min 81.27 5.953 84.13 5.532 0.06 
10 min 79.8 6.178 82.27 5.771 0.115 
15 min 77.73 5.65 80.47 5.912 0.072 
20 min 76.6 5.876 80.4 5.642 0.013 
25 min 73.07 6.297 78.9 6.799 0.001 
30 min 72.8 7.251 77.2 6.8 0.018 
45 min 72.93 6.533 77.07 6.533 0.017 
60 min 76.97 7.828 78.87 6.404 0.31 
75 min 77.87 7.314 79.07 6.448 0.50 
90 min 77.79 6.915 79.79 5.425 0.22 
120 min 79.44 5.933 79.56 4.731 0.96 
150 min 80.60 4.76 81.40 4.04 0.49 
180 min 81.27 4.09 82.13 4.55 0.44 
 
 
65
70
75
80
85
90
Group A
Group B
77 
MEAN ARTERIAL BLOOD PRESSURE 
The following table shows that the comparison of systolic blood pressure 
variations between the two groups showed significant statistical difference 
(p<0.05) 
TIME 
GROUP A GROUP B 
p value 
MEAN SD MEAN SD 
baseline 127.13 7.00 124.40 5.91 0.11 
0 min 79.27 5.39 77.00 5.30 0.11 
5 min 85.63 7.393 88.23 7.065 0.17 
10 min 85.3 7.585 88.27 6.108 0.10 
15 min 79.50 6.31 86.03 6.30 0.00 
20 min 79.77 7.17 85.83 7.30 0.00 
25 min 77.67 5.90 82.37 8.76 0.02 
30 min 74.93 4.96 82.47 7.72 0.00 
45 min 76.07 4.14 83.30 7.75 0.00 
60 min 63.00 3.89 71.87 5.58 0.00 
75 min 80.37 3.16 89.60 7.42 0.00 
90 min 85.10 3.16 90.60 4.36 0.00 
120 min 88.4 4.438 89.9 4.163 0.18 
150 min 92.53 3.25 93.17 4.07 0.51 
180 min 95.53 3.81 94.87 4.28 0.53 
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COMPARISON OF OXYGEN STAURAION (Student’s t test) 
The following table shows oxygensaturation between two groups. There 
was no significant statistical difference in both the groups (p>0.05) 
TIME 
GROUP A GROUP B 
p value 
MEAN SD MEAN SD 
baseline 99.63 0.61 99.80 0.41 0.22 
0 min 99.57 0.63 99.57 0.63 1.00 
5 min 99.63 0.56 99.67 0.55 0.82 
10 min 99.47 0.63 99.63 0.56 0.28 
15 min 99.47 0.63 99.57 0.63 0.54 
20 min 99.43 0.504 99.63 0.49 0.12 
25 min 99.40 0.62 99.63 0.49 0.11 
30 min 99.40 0.62 99.57 0.68 0.33 
45 min 99.37 0.61 99.60 0.50 0.11 
60 min 99.50 0.51 99.50 0.50 0.35 
75 min 99.37 0.61 99.50 0.63 0.41 
90 min 99.50 0.51 99.60 0.56 0.47 
120 min 99.53 0.57 99.70 0.60 0.27 
150 min 99.80 0.48 99.93 0.37 0.23 
180 min 99.93 0.25 100.00 0.00 0.16 
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SIDE EFFECTS: 
Side Effects Group A (no of patients) Group B (no of patients) 
Nausea 1 5 
Vomiting 0 2 
Shivering 0 1 
Pruritus 0 1 
Bradycardia 3 0 
Hypotension 7 4 
Dry mouth 3 0 
Respiratory depression 0 0 
Urinary retention 0 0 
 
              
Patient in group A had   bradycardia , hypotension, dry mouth and group 
B had  nausea , vomiting , hypotension as main side effects . Group B patients 
also had shivering and pruritus as adverse effects . None of the patients had 
respiratory depression  in both groups.  
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DISCUSSION 
Epidural anaesthesia is used as a sole anaesthetic technique  for   lower 
orthopedic surgeries  to provide postoperative analgesia  and  for   early 
ambulation.   Adjunvant  drugs used along with  the epidural anaesthesia can  
modify  local  anaesthetic effects . They reduce latency ,  prolong the duration  
and improve quality of anaesthesia . Opioids, Adrenergic stimulators ,GABA 
receptor agonists, NMDA receptor antagonists, Cholinesterase inhibitors are 
used as neuraxial adjuvants and reviews of various studies are  available (34) .  
In our study, Group A received  15ml of 0.5 % ropivacaine with  1 µg/ kg  
of  Dexmedtomidine  and group B received   15ml  of  0.5% ropivacaine  with  
1 µg/ kg of fentanyl  .  
The efficacy and analgesic  effects of dexmedetomidine and fentanyl with 
epidurally administered ropivacaine was studied in 30 patients in each group  for 
patients undergoing lower limb orthopedic surgeries 
The patients in both groups did not  Show  any  statistically  significant 
difference with respect to age, weight, sex   .  
ONSET OF SENSORY BLOCK AT T10 LEVEL : 
In our study ,   addition of 1 µg / kg of dexmedetomidine to 15 ml of 0.5% 
ropivacaine in group A  reduced the onset time for sensory block when  
compared to  0.5% ropivcaine with1 µg / kg of fentanyl in group B .  The mean 
time for onset of sensory block at T 10  is 3.87±0.681 (minutes)in group A and 
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6.03±1.47(minutes) in group  B . Early sensory  onset time was  observed  in 
group A. The study of Sukhminder jit singh bajwa et al(23),   
Rashpal Singh Gill et al(24)  and Kumkum Gupta et al(25),  Bhawana Rastogi et 
al(27)  were  also correlated with the same results  when dexmedetomidine was 
used as an adjuvant to Ropivacaine  . 
MAXIMUM SENSORY LEVEL ACHIEVED: 
In our study , maximum sensory level achieved was T4-8  dermatome 
with dexmedetomidine as an adjuvant to ropivacaine(group A ). Maximum 
sensory level achieved was T6 - 10 dermatome with fentanyl as an adjuvant  
to Ropivacaine (group B). Difference in the maximum sensory level  
achieved in the two groups was highly significant (P < 0.001).    
Sukhminder jit singh bajwa et al, (23) and Sarabjit Kaur,et al(26) studies also 
showed similar result that group with Dexmedetomidine as an adjuvant to 
Ropivacaine  had  maximum sensory level of T4 and T 5 respectively.  
TIME TAKEN FOR COMPLETE MOTOR BLOCKADE:    
In our study , Complete motor block was achieved earlier in group A than 
group B. The study had shown that addition of 1 µg/ kg of dexmedetomidine to 
15 ml of  0.5% ropivacaine  in group A  had  time for  complete motor block  of   
19±3.151   minutes earlier  when  compared to group B addition of 1 µg/ kg of 
fentanyl to  0.5% 15 ml of ropivcaine with  time for complete motor block of  
23.37±2.58 minutes.  This results was correlated with following studies   
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1) Sukhminder jit singh bajwa, et al (23) where they had shown that 
addition of 1 µg/ kg of dexmedetomidine to 15 ml of 0.75% ropivacaine  
in group RD resulted in  earlier achievement of complete motor blockade 
(18.16±4.52) than in group RF(22.98±4.78) who had recieved   1 µg/ kg 
of fentanyl to  0.75% 15 ml of ropivcaine  
2) Rashpal Singh Gill at al(24)  observed that  attainment of complete  motor 
block  was significantly faster  in Group RD (dexmedetomidine1 µg/kg + 
0.75% ropivcaine) when compared with group RF (fentanyl 1 µg/kg + 
0.75% ropivcaine). (Group RD vs RF 19.86±1.66 vs 27.72±1.21) 
(P=0.003). 
3)  Kumkum Gupta et al(25) this study aimed to compare  the effects of 
adding Dexmedetomidine and fentanyl with levobupivacaine  for epidural 
anaesthesia. They  concluded  that  time  to attain  complete motor 
blockade (19.27 ± 4.7 versus 22.78 ± 5.57 min) was significantly earlier 
in group LD (dexmedetomidine with levobupivacaine group) than  
group LF ( Fentanyl with levobupivacaine ) 
SEDATION SCORE : 
In our study , sedation score was assessed by observer ‘s assessment of 
alertness / sedation score . Group A patients had   better and easily arousable 
sedation score  of 1-3  where as  group B patients  had sedation score of  1-2 . 
Better sedation score was observed in (dexmedetomidine and ropivacaine)  
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group A when   compared to  (fentanyl and ropivacine) group B . This result was 
also concurrent  with studies of  Sukhminder jit singh bajwa et al (23) ,  
Rashpal Singh Gill at al(24), Kumkum Gupta et al (25) . 
DURATION OF SENSORY BLOCK : 
Our study showed that the duration of sensory block was prolonged in 
group A where  dexmedetomidine used as adjuvant to epidural ropivacaine  than 
group B where fentanyl as adjuvant to epidural ropivacaine .In group A the 
duration of sensory block was 335.83±41.316 minutes   compared to group B  
which was285.37±25.914  minutes.P (<0.05).This result was concurrent with  
1) Sarabjit Kaur, et al (26)  where they concluded that sensory block 
duration is significantly  prolonged  in  ropivacaine dexmedetomidine 
group B 590.61 ± 80.30 minutes than ropivacaine alone  group A   
535.18 ± 19.85  minutes, (p=0.000) 
2) MS Saravana babu et al(29) , Compared the addition of dexmedetomidine 
with ropivacaine (RD)  and ropivacaine with clonidine  (RC)for epidural 
anaesthesia , they concluded  that the duration of  analgesia was also 
prolonged in dexmedetomidine group (407.00±47.06 min) compared to 
clonidine group (345.01±35.02). 
TIME OF FIRST RESCUE ANALGESIA :  
Our study showed that addition of  dexmedetomidine to  ropivacaine  in 
group A  prolongs the duration of  analgesia and prolongs the  patients  first 
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analgesic request, 373.67±45.636  minutes, when compared to  addition of 
fentanyl to ropivacaine   in group B  314.1±28.403 . This result  was correlated 
with following studies   
1) Sukhminder jit singh bajwa et al(23) observed that duration of 
requirement of first rescue  analgesia was significantly longer in  group 
RD than in group R (P< 0.001) .They found that duration of analgesia  
was 366.62±24.42  minutes in ropivacaine dexmedetomidine group  and    
was 242.16±23.86  minutes   in ropivacaine fentanyl group.(P <0.0001) 
2) This  result also correlated with the study Rashpal Singh Gill at al(24)  
where they concluded that adding dexmedetomidine to epidural 
ropivacaine   increases the time to first analgesic use  and also in studies 
conducted by Sarabjit Kaur et al (26),Salgado PF et al(30)  and Bhawana 
Rastogi et al (27)  . 
HEMODYNAMIC STABILITY : 
            Heart rate remained stable in the range of 56 to 88 /min in the group A 
and  in range of 62 to 90 / min . Mean arterial pressure (MAP) decreased from 
the baseline in both   groups  but   never went below 65 mmHg. Significant 
hypotension and bradycardia were observed in group A( dexmedetomidine with 
ropivacaine ) but manageable with intravenous atropine and ephedrine  and  this  
result  was correlated with the study  of Sukhminder jit singh bajwa, et al(23) . 
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SIDE -EFFECTS  : 
In our study,  dry mouth ,  bradycardia and hypotension was observed 
more in GroupA.  Nausea , vomiting were side effects observed in  Group  B  . 
None of the patient in both groups had respiratory depression and these  
observations were also found in studies of Sukhminder jit singh bajwa, et al(23)   
and Rashpal Singh Gill at al(24)  . 
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SUMMARY 
A double blinded prospective randomized  study was done  to evaluate  
and compare the efficacy,analegsic effects, postoperative analgesia of 
dexmedetomidine or  fentanyl with epidurally administered ropivacaine for 
patients undergoing lower limb orthopedic  surgeries.The onset of sensory block 
at T 10 level ,time taken for complete  motor block, duration of  analgesia and 
time to rescue analgesia and side effects  were observed using  1µg /kg of 
dexmedetomidine with 15 ml of 0.5% ropivacaine (Group A ) versus 1µg /kg of 
fentanyl  with 15 ml of 0.5% ropivacaine  (Group B) for epidural anaesthesia . 
The onset of sensory  block assessed by loss of cold sensation and motor block 
by  bromage score . Duration of  analgesia and time to rescue analgesia  were 
assessed in our study. Hemodynamic  parameters such as pulse rate ,  blood 
pressure and oxygen saturation were monitored .postoperative  pain is assessed 
using visual analogue scale. If VAS 4and above rescue analgesics is 
administered. The following observations were made :  
1. Addition of dexmedetomidine as adjuvant to epidural ropivacaine, 
produced early onset of sensory and motor block  when compared to 
epidural fentanyl . 
2. Addition of dexmedetomidine significantly prolonged the duration of 
analgesia and the  time for  first rescue  analgesia when compared to 
epidural fentanyl . 
87 
3. Better  and easy arousable sedation score was observed when 
dexmedetomidine used as adjuvant than epidural fentanyl  . 
4. Side effects such as bradycardia and hypotension were more in patients 
who received dexmedetomidine as adjuvant to ropivacaine . but easily 
managed with injection atropine   and ephedrine . 
5. None of the patients had respiratory depression  in both groups.  
Thus the addition of dexmedetomidine to  epidural ropivacaine fastens the 
onset  time of sensory block ,increases duration of analgesia  and provides  better 
sedation when compared with fentanyl  used as adjuvant  to epidural ropivacaine  
with minimal side effects .  
LIMITATIONS OF THE STUDY 
} Patients belongs to ASAI/II. 
} Since blood loss varies with different types of orthopedic surgeries. 
comparision  of haemodynamic changes  was less reliable , as 
haemodynamic parameters which also depends on blood loss  .  
} As the patients  were undergoing  lower limb orthopedic  surgery, patients 
were  immobile the measurements of body weight was impossible . Hence 
a nomogram was used to calculate the body weight .  
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CONCLUSION 
 To conclude , dexmedetomidine seems to be a better adjuvant to epidural 
ropivacaine for lower limb orthopedic surgeries  for attaining  early  onset of 
sensory and motor block ,  providing better sedation  and prolonging  sensory 
blockade   when compared to epidural fentanyl with minimal  side effects . 
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LIST OF ABBREVIATIONS 
ASA  - American Society of Anaesthesiologist 
BP        - Blood Pressure 
PR   - pulse rate  
CNS   - Central nervous system 
CVS   - Cardiovascular system  
I.V   - Intravenous  
Kg    - Kilogram 
mA    - Milliampere  
mv    - Millivolt             
µg    - Microgram 
mg    - Milligram 
ml    - Millilitre  
MAP   - Mean Arterial Pressure 
spO 2   - Oxygen saturation 
VAS   - Visual Analog Score 
SD    - standard deviation  
G    - Gauge  
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PROFORMA 
v Name : 
v Age  /sex: 
v IP no : 
v Date of admission : 
v Date of surgery : 
v Address for communication: 
v Contact no: 
v Diagnosis : 
v Surgery : 
v Weight : 
v PR: 
v BP: 
v CVS: 
v RS: 
v ABDOMEN: 
v CNS: 
v Mallampati classification class: 
v ASA PS class : 
v Investigations : 
ü Hb: 
ü TC 
ü DC 
ü Platelets 
ü RFT: 
ü Urine routine: 
ü ECG: 
ü CXR: 
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ü Electrolytes: 
ü Others : 
v Premedication : 
 
v Preloading: 
 
v Drugs given  in epidural: 
 
v Time of sensory  onset  at T 10 : 
 
v Maximum sensory level achieved: 
 
v Time taken for complete motor block :  
 
v Sedation score 
 
v Total duration of analgesia: 
 
v Time of first rescue analgesia given: 
 
v Other side effects 
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SEDATION SCORE : 
TIME   SEDATION SCORE  
0 min 
15 mins 
30 mins  
45 mins 
60 mins  
120 mins  
180 mins  
 
Haemodynamic parameters : 
TIME PR/min 
NIBP (mm/Hg) 
Sp02% 
SBP DBP MAP 
0 min      
5 min      
10 min      
15 min      
20 min      
25 min      
30 min      
45 min      
60 min      
75  min      
90 min      
120 min      
150 min       
180 min      
 
98 
 
 
INFORMATION SHEET 
 
Ø We are conducting a study on “Comparative study of dexmedetomidine and 
fentanyl as adjuvant  to epidural  ropivacaine for lower limb Orthopedic 
surgeries” 
Ø The purpose of the study is to find whether dexmedetomidine will be a better 
alternative to fentanyl as an adjunct to epidural ropivacaine . 
Ø The privacy of the patient in the research will be maintained throughout the 
study. In the event of any publication or presentation resulting from the 
research , no personally identifiable information will be shared. 
Ø Taking part in the study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time. Your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
Ø The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may aid 
in the management or treatment. 
 
 
Signature of investigator                          Signature of patient /guardian 
 
Date : 
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MASTER CHART 
 
S.No Group Name Surgery 
Time Of Sensory 
Onset At T10 
Level (Mins) 
Maximum 
Sensory Level 
Achieved 
Time Taken For 
Complete Motor 
Block (Mins) 
Total Duration 
Of Analgesia 
(Mins) 
Time Of First 
Rescue Analgesia 
(Mins) 
Side Effects 
1 A MAHENDRAN FEMUR NAILING 4 T6 15 360 420 DRY MOUTH 
2 A YEGADI FEMUR NAILING 3 T6 15 380 410 0 
3 A ALEXANDER EXTERNAL FIXATION OF TIBIA 4 T6 20 370 400 0 
4 A DHAYALAN TIBIAL NAILING 3 T6 15 320 340 0 
5 A ASHOK TIBIAL NAILING 4 T4 20 420 450 HYPOTENSION 
6 A NAVEEDHAM TIBIAL NAILING 3 T6 15 345 375 0 
7 A VELU FEMUR NAILING 3 T8 15 320 360 BRADYCARDIA 
8 A HARIKRISHNAN TOTAL HIP REPLACEMENT 4 T6 20 330 355 0 
9 A THULASI DASS TIBIAL NAILING 4 T4 20 410 455 0 
10 A SUNDRAMOORTHY TIBIAL NAILING 4 T6 20 310 340 BRADYCARDIA 
11 A RAJESEKAR TIBIAL NAILING 5 T6 20 280 310 0 
12 A SUBBU FEMUR NAILING 4 T6 20 320 370 0 
13 A SAMANTHAMMAL HEMIARTHROPLASTY 3 T4 15 380 430 HYPOTENSION 
14 A ELUMALAI FEMUR NAILING 3 T6 20 350 385 BRADYCARDIA,HYPOTENSION 
15 A LAKSHMAN TIBIAL NAILING 4 T6 20 315 340 0 
16 A EZHUMALAI FEMUR NAILING 5 T6 20 300 335 DRY MOUTH 
17 A AMITH KUMAR FEMUR NAILING 4 T6 15 360 415 0 
18 A SUGAN FEMUR NAILING 4 T4 15 400 440 HYPOTENSION 
19 A REVATHY TIBIAL NAILING 4 T6 20 310 350 0 
20 A KABALI TIBIAL NAILING 5 T6 20 300 335 HYPOTENSION 
21 A DEVA TIBIAL NAILING 5 T8 25 280 310 0 
22 A SRINIVASAN FEMUR NAILING 4 T8 25 260 295 HYPOTENSION 
23 A SHANKAR TIBIAL NAILING 4 T6 20 310 340 0 
24 A SRINIVASAN TIBIAL NAILING 5 T8 25 285 330 0 
25 A RAJA TIBIAL NAILING 4 T8 20 305 335 NAUSEA 
26 A RAMESH TIBIAL NAILING 3 T6 20 320 365 0 
27 A ELLAMMAL TIBIAL NAILING 3 T6 20 355 430 HYPOTENSION 
28 A CHANDRAN FEMUR NAILING 3 T4 15 390 435 0 
29 A JAYARAMAN TOTAL KNEE REPLACEMENT 4 T6 20 370 400 DRY MOUTH 
30 A DEVA BABU ARTHROSCOPIC LIG REPAIR 4 T6 20 320 355 0 
S.No Group Name Surgery 
Time Of Sensory 
Onset At T10 
Level (Mins) 
Maximum 
Sensory Level 
Achieved 
Time Taken For 
Complete Motor 
Block (Mins) 
Total Duration 
Of Analgesia 
(Mins) 
Time Of First 
Rescue Analgesia 
(Mins) 
Side Effects 
1 B VENKADESAN FEMUR NAILING 4 T10 30 300 315 NAUSEA 
2 B VENGADESAN TIBIAL NAILING 6 T8 20 320 340 0 
3 B BABU TIBIAL NAILING 7 T8 25 310 325 VOMITING 
4 B VEERARAGHVAN HEMIARTHROPLASTY 8 T8 20 280 305 0 
5 B SURESH TIBIAL NAILING 8 T10 25 330 400 HYPOTENSION 
6 B UMADEVI HEMIARTHROPLASTY 5 T8 20 320 355 0 
7 B THANGARAJ TIBIAL NAILING 6 T8 25 280 315 NAUSEA 
8 B ASHOK FEMUR NAILING 4 T6 20 310 325 0 
9 B SUDHAN FEMUR NAILING 6 T8 25 290 315 0 
10 B KATHAVARAYAN FEMUR NAILING 6 T8 25 270 305 HYPOTENSION 
11 B BABU SHARIFF TIBIAL NAILING 9 T8 25 280 320 0 
12 B SUBRAMANI TOTAL KNEE REPLACEMENT 5 T8 25 280 315 0 
13 B SUJATHA ARTHROSCOPIC LIG TEAR 9 T8 20 300 340 NAUSEA 
14 B ARVINDHAN FEMUR NAILING 4 T6 15 315 330 0 
15 B SARATH KUMAR FEMUR NAILING 5 T6 20 300 328 0 
16 B AMSA ARTHROSCOPIC LIG TEAR 9 T8 25 260 280 SHIVERING 
17 B ELUMALAI FEMUR NAILING 5 T6 20 270 295 HYPOTENSION 
18 B SUMAN FEMUR NAILING 5 T8 25 300 320 0 
19 B ARUMUGAM TIBIAL NAILING 6 T6 20 280 315 0 
20 B VELU FEMUR NAILING 5 T8 25 275 300 NAUSEA 
21 B LAKSHMINARAYAN TIBIAL NAILING 5 T8 25 240 275 0 
22 B VELU TIBIAL NAILING 5 T8 25 280 310 HYPOTENSION 
23 B ALEXANDER TIBIAL NAILING 5 T6 25 300 325 0 
24 B DEVASAGYAM FEMUR NAILING 6 T8 25 250 280 VOMITING 
25 B ADHI HEMIARTHROPLASTY 6 T6 20 280 320 0 
26 B JOHN TOTAL HIP REPLACEMENT 8 T10 25 220 245 NAUSEA 
27 B GOPAL HEMIARTHROPLASTY 7 T8 25 270 310 0 
28 B RAMACHANDRAN ARTHROSCOPIC LIG TEAR 6 T8 25 240 265 0 
29 B SIVAPRASKASAM HEMIARTHROPLASTY 5 T8 25 300 320 0 
30 B CHINNAPONNU FEMUR PLATING 6 T6 25 305 330 PRURITUS 
 
 
SEDATION SCORE 
 
S.No Group 0min 15 min 30 min 45min 60 min 120 min 180 min 
1 A 1 1 2 2 2 1 1 
2 A 1 1 1 2 1 1 1 
3 A 1 1 1 1 1 1 1 
4 A 1 1 2 2 1 1 1 
5 A 1 1 2 2 1 1 1 
6 A 1 1 2 2 2 1 1 
7 A 1 1 2 2 2 2 1 
8 A 1 1 2 2 2 2 1 
9 A 1 1 2 2 2 1 1 
10 A 1 1 1 2 1 1 1 
11 A 1 1 1 1 1 1 1 
12 A 1 1 1 2 2 1 1 
13 A 1 1 2 2 3 2 1 
14 A 1 1 2 2 2 1 1 
15 A 1 1 1 1 1 1 1 
16 A 1 1 1 1 1 1 1 
17 A 1 1 1 1 1 1 1 
18 A 1 1 2 2 2 1 1 
19 A 1 1 2 2 2 1 1 
20 A 1 1 1 1 1 1 1 
S.No Group 0min 15 min 30 min 45min 60 min 120 min 180 min 
21 A 1 1 1 1 1 1 1 
22 A 1 1 1 1 1 1 1 
23 A 1 1 2 2 2 1 1 
24 A 1 1 1 1 1 1 1 
25 A 1 1 2 2 2 1 1 
26 A 1 1 2 3 2 1 1 
27 A 1 2 3 3 3 1 1 
28 A 1 1 2 3 3 2 1 
29 A 1 1 2 2 2 1 1 
30 A 1 1 1 1 1 1 1 
1 B 1 1 1 1 1 1 1 
2 B 1 1 1 1 1 1 1 
3 B 1 2 2 2 1 1 1 
4 B 1 1 1 1 1 1 1 
5 B 1 1 1 1 1 1 1 
6 B 1 1 1 1 1 1 1 
7 B 1 1 1 1 1 1 1 
8 B 1 1 2 2 1 1 1 
9 B 1 1 1 1 1 1 1 
10 B 1 1 1 1 1 1 1 
11 B 1 1 1 1 1 1 1 
12 B 1 1 1 1 1 1 1 
S.No Group 0min 15 min 30 min 45min 60 min 120 min 180 min 
13 B 1 1 1 1 1 1 1 
14 B 1 2 2 2 2 1 1 
15 B 1 1 2 2 1 1 1 
16 B 1 1 1 1 1 1 1 
17 B 1 1 2 1 1 1 1 
18 B 1 1 1 1 1 1 1 
19 B 1 1 1 1 1 1 1 
20 B 1 1 1 1 1 1 1 
21 B 1 1 1 1 1 1 1 
22 B 1 1 1 1 1 1 1 
23 B 1 1 1 1 1 1 1 
24 B 1 1 1 1 1 1 1 
25 B 1 1 2 2 2 1 1 
26 B 1 1 1 1 1 1 1 
27 B 1 1 1 1 1 1 1 
28 B 1 1 1 1 1 1 1 
29 B 1 1 2 2 1 1 1 
30 B 1 1 2 2 2 1 1 
 
  
PULSE RATE (PER MIN) 
 
S.No Group PR BASE LINE 
PR 
0MIN 
PR 
5MIN 
PR 
10MIN 
PR 
15MIN 
PR 
20MIN 
PR 
25MIN 
PR 
30MIN 
PR 
45MIN 
PR 
60MIN 
PR 
75MIN 
PR 
90MIN 
PR 
120MIN 
PR 
150MIN 
PR 
180MIN 
1 A 88 80 76 72 78 72 74 80 84 82 86 90 82 86 84 
2 A 90 90 88 76 74 72 76 78 80 84 84 82 80 80 80 
3 A 88 84 82 86 84 84 82 82 82 80 82 78 84 86 88 
4 A 82 90 80 78 78 76 72 70 70 72 76 84 82 82 86 
5 A 92 78 72 78 76 72 62 60 78 78 78 80 84 82 80 
6 A 78 68 68 70 72 72 68 64 64 66 66 68 72 70 76 
7 A 86 84 84 76 72 78 72 76 54 60 62 68 76 72 80 
8 A 72 78 80 82 78 76 78 76 78 82 80 80 82 84 82 
9 A 70 78 72 70 72 72 70 70 74 70 68 70 76 78 76 
10 A 88 82 80 72 70 70 68 60 52 58 68 76 82 84 82 
11 A 90 84 82 82 84 84 84 82 84 84 84 82 84 86 88 
12 A 88 82 84 82 82 84 84 74 72 78 84 84 82 82 86 
13 A 82 88 76 72 84 82 82 84 76 84 84 82 84 82 82 
14 A 78 72 70 70 76 74 60 54 58 60 62 64 78 80 80 
15 A 86 80 80 80 80 80 82 82 84 82 82 84 82 80 82 
16 A 82 80 86 84 84 82 80 80 78 78 78 80 82 82 80 
17 A 88 90 88 72 70 68 70 72 72 76 78 72 76 86 84 
18 A 86 76 78 76 78 80 68 68 64 72 68 66 70 78 78 
19 A 88 82 78 76 76 78 82 80 82 80 82 82 80 82 82 
20 A 82 86 78 80 82 82 80 80 84 76 76 78 80 82 80 
21 A 86 84 84 82 84 82 84 84 84 83 82 82 80 82 86 
22 A 78 80 86 84 80 72 70 72 84 86 82 82 92 88 86 
23 A 88 86 82 84 84 82 84 84 84 82 82 80 82 86 82 
24 A 78 84 82 82 82 82 82 82 82 82 82 82 78 78 80 
25 A 76 80 78 78 72 70 72 78 80 76 84 82 80 76 78 
26 A 88 82 80 80 78 78 78 78 80 82 84 82 80 78 80 
27 A 72 68 66 62 60 60 64 62 64 68 66 64 64 68 68 
28 A 88 82 82 82 82 80 80 78 82 82 82 80 80 80 80 
29 A 78 76 78 76 78 72 68 72 70 82 82 70 78 76 78 
30 A 88 84 84 84 82 82 84 84 82 84 82 84 80 82 84 
1 B 82 88 88 86 86 86 78 72 78 82 82 82 84 74 72 
2 B 78 90 84 84 82 82 80 78 76 82 84 82 76 78 78 
S.No Group PR BASE LINE 
PR 
0MIN 
PR 
5MIN 
PR 
10MIN 
PR 
15MIN 
PR 
20MIN 
PR 
25MIN 
PR 
30MIN 
PR 
45MIN 
PR 
60MIN 
PR 
75MIN 
PR 
90MIN 
PR 
120MIN 
PR 
150MIN 
PR 
180MIN 
3 B 82 84 84 84 82 84 84 82 84 84 82 80 78 80 78 
4 B 88 88 92 90 86 84 88 88 88 92 88 88 86 84 88 
5 B 88 72 88 72 68 70 72 70 68 68 70 78 72 78 80 
6 B 84 90 92 88 78 76 78 82 84 82 84 82 78 86 88 
7 B 76 78 72 80 82 76 70 72 70 70 68 70 78 78 80 
8 B 88 88 78 80 78 80 78 78 80 78 80 80 78 80 80 
9 B 82 78 78 80 82 84 70 68 66 70 72 80 82 82 80 
10 B 86 88 88 90 86 88 86 86 78 82 80 82 76 86 80 
11 B 88 92 90 88 90 88 84 82 80 84 82 82 84 88 88 
12 B 80 88 84 86 84 86 82 86 86 84 86 82 78 82 80 
13 B 90 88 88 82 80 80 82 82 82 80 78 78 82 86 82 
14 B 90 98 90 88 84 86 82 76 78 80 82 78 82 86 86 
15 B 82 88 86 86 88 80 78 82 80 78 72 76 72 82 86 
16 B 86 78 78 72 76 78 70 68 72 70 72 74 78 76 78 
17 B 68 68 68 70 64 64 62 62 64 64 66 62 70 72 70 
18 B 86 90 86 82 82 80 82 80 84 84 84 86 80 82 86 
19 B 82 82 80 78 78 72 78 74 70 78 72 80 76 80 82 
20 B 82 88 86 82 84 84 83 72 72 78 72 80 82 80 82 
21 B 90 86 78 72 74 76 68 70 72 78 78 78 76 82 86 
22 B 78 80 84 76 72 76 78 72 74 72 72 74 78 76 80 
23 B 86 84 88 78 76 78 80 82 80 84 86 82 82 84 86 
24 B 86 86 84 86 84 82 82 72 72 76 76 78 78 78 82 
25 B 88 82 84 82 82 80 80 82 82 82 84 82 86 84 88 
26 B 82 88 84 86 84 84 88 82 82 84 82 88 86 84 86 
27 B 72 86 84 84 82 82 82 82 68 80 82 80 80 78 80 
28 B 88 88 88 90 76 78 68 68 74 70 84 82 80 86 82 
29 B 86 84 82 78 76 78 82 78 82 82 80 82 84 84 82 
30 B 90 98 88 88 88 90 92 88 86 88 92 88 88 86 88 
 
  
BLOOD PRESSURE (mm Hg) 
 
S.No Group BASE LINE SBP 
BASE 
LINE DBP 
BASE  
LINE MAP 
0 MIN 
SBP 
0 MIN 
DBP 
0 MIN 
MAP 
5 MIN 
SBP 
5 MIN 
DBP 
5 MIN 
MAP 
10 MIN 
SBP 
10 MIN 
DBP 
10 MIN 
MAP 
15 MIN 
SBP 
15 MIN 
DBP 
15 MIN 
MAP 
1 A 126 88 100 118 72 87 108 66 80 120 72 88 116 62 78 
2 A 128 88 101 112 68 82 96 68 77 112 70 84 98 68 78 
3 A 128 78 94 137 80 98 124 78 93 136 82 100 124 80 94 
4 A 142 78 99 132 88 102 112 74 86 112 70 84 122 72 88 
5 A 132 88 102 130 80 96 110 68 82 96 64 72 90 66 74 
6 A 118 78 91 112 70 84 98 68 78 112 66 81 112 68 82 
7 A 138 86 102 128 78 94 112 70 84 112 72 85 108 68 81 
8 A 130 78 95 131 85 101 112 70 84 118 72 87 108 62 77 
9 A 112 70 84 118 70 86 90 54 66 98 56 70 96 56 69 
10 A 126 82 96 112 76 88 112 72 85 116 68 84 114 68 83 
11 A 126 82 96 128 80 96 116 72 86 124 76 92 116 70 85 
12 A 140 82 101 128 88 101 112 74 86 112 70 84 102 68 79 
13 A 128 86 100 130 78 95 112 60 77 108 62 77 112 60 77 
14 A 122 76 91 124 78 93 120 76 90 118 72 87 118 70 86 
15 A 128 80 96 127 85 100 112 76 88 120 72 88 116 70 85 
16 A 118 72 87 124 80 94 112 70 84 116 70 85 108 70 82 
17 A 118 80 92 112 76 88 108 70 82 98 60 72 92 60 70 
18 A 124 78 94 132 80 97 112 70 84 100 68 78 90 54 66 
19 A 132 80 97 127 85 100 118 70 86 116 70 85 112 68 82 
20 A 112 74 86 128 72 90 112 70 84 114 72 86 108 70 82 
21 A 130 72 91 134 78 96 130 78 95 128 74 92 112 60 72 
22 A 132 78 96 118 72 87 100 68 78 102 70 80 116 68 84 
23 A 128 72 90 128 82 97 138 88 103 132 86 101 108 70 82 
24 A 126 74 91 118 78 91 120 74 89 120 72 88 112 60 72 
25 A 132 82 98 126 72 90 112 70 84 108 68 81 112 68 82 
26 A 130 78 95 128 80 96 128 82 97 132 80 97 112 60 77 
27 A 132 86 101 128 88 101 132 80 97 112 70 83 108 72 84 
28 A 128 86 100 130 80 96 130 80 96 136 80 98 100 66 77 
29 A 124 74 90 132 78 96 118 70 86 112 70 84 108 60 76 
30 A 124 72 89 128 80 96 108 70 82 118 70 86 116 68 84 
S.No Group BASE LINE SBP 
BASE 
LINE DBP 
BASE  
LINE MAP 
0 MIN 
SBP 
0 MIN 
DBP 
0 MIN 
MAP 
5 MIN 
SBP 
5 MIN 
DBP 
5 MIN 
MAP 
10 MIN 
SBP 
10 MIN 
DBP 
10 MIN 
MAP 
15 MIN 
SBP 
15 MIN 
DBP 
15 MIN 
MAP 
1 B 120 72 88 124 80 94 126 78 94 128 78 94 126 76 91 
2 B 128 76 93 136 80 98 108 68 81 118 70 86 126 70 88 
3 B 126 74 91 122 78 92 114 74 87 120 72 88 114 68 83 
4 B 118 72 87 124 70 88 132 72 92 128 74 92 120 70 86 
5 B 134 80 98 126 72 90 110 72 84 112 68 82 122 70 87 
6 B 118 78 91 120 74 89 112 70 84 114 74 87 120 72 90 
7 B 124 70 88 126 72 90 108 70 82 108 68 81 112 70 84 
8 B 132 78 96 116 70 85 106 72 83 124 72 89 122 74 90 
9 B 124 74 90 132 88 103 124 72 89 122 78 92 122 72 88 
10 B 128 82 97 132 86 101 112 70 84 112 70 84 112 70 84 
11 B 132 88 103 132 82 98 132 88 103 128 86 100 130 80 97 
12 B 120 72 88 132 88 102 132 80 97 132 80 97 124 78 93 
13 B 132 86 101 126 74 93 116 76 89 112 70 84 118 72 87 
14 B 118 80 92 128 78 94 114 74 87 108 68 81 118 70 86 
15 B 126 72 90 128 86 100 118 80 92 116 76 89 112 70 84 
16 B 128 74 92 112 76 88 100 68 78 110 72 84 112 68 72 
17 B 118 74 88 126 72 90 98 68 78 112 70 84 112 68 72 
18 B 124 82 96 112 80 90 108 70 82 124 78 93 122 74 90 
19 B 112 70 84 120 86 97 112 80 90 116 76 89 112 70 84 
20 B 124 72 89 124 80 100 110 72 84 108 70 82 100 68 78 
21 B 128 86 100 132 86 101 130 78 95 128 74 92 124 80 90 
22 B 124 74 90 132 88 102 100 68 78 102 70 80 112 70 84 
23 B 132 80 97 142 86 104 138 88 103 132 86 101 130 80 97 
24 B 124 82 96 108 72 84 120 74 89 120 72 88 112 70 84 
25 B 112 72 85 132 88 102 112 70 84 108 68 81 112 70 84 
26 B 130 74 94 142 86 104 128 82 97 132 80 97 112 74 86 
27 B 120 74 89 148 88 108 132 80 97 112 70 83 98 60 72 
28 B 122 86 98 122 80 94 130 80 96 136 80 98 128 78 94 
29 B 122 74 90 120 72 90 118 70 86 112 70 84 124 70 88 
30 B 132 82 98 132 80 97 108 70 82 118 70 86 126 70 88 
 
  
BLOOD PRESSURE (Contd…) 
 
S.No Group 20 MIN SBP 
20 MIN 
DBP 
20 MIN 
MAP 
25 MIN 
SBP 
25 MIN 
DBP 
25 MIN 
MAP 
30 MIN 
SBP 
30 MIN 
DBP 
30 MIN 
MAP 
45 MIN 
SBP 
45 MIN 
DBP 
45 MIN 
MAP 
60 MIN 
SBP 
60 MIN 
DBP 
60 MIN 
MAP 
1 A 116 68 84 104 66 78 100 60 73 106 60 75 100 60 66 
2 A 96 68 77 108 70 82 112 68 82 96 64 74 106 66 79 
3 A 128 86 100 112 68 82 112 66 81 112 66 81 116 62 78 
4 A 106 70 82 102 70 80 98 68 78 100 68 78 112 68 82 
5 A 110 70 83 110 72 84 90 54 66 92 56 68 100 60 73 
6 A 118 66 83 104 64 77 104 62 76 112 66 81 112 68 82 
7 A 108 68 81 100 66 77 112 68 82 116 68 84 104 66 78 
8 A 108 68 81 100 66 77 98 60 72 102 60 74 100 60 73 
9 A 98 64 75 100 74 82 116 64 81 112 64 80 98 66 76 
10 A 112 60 77 102 68 79 96 60 72 100 62 74 92 60 70 
11 A 116 72 86 100 68 78 102 66 78 104 64 77 102 60 74 
12 A 100 66 77 100 64 76 102 66 78 102 64 77 112 68 82 
13 A 126 70 88 118 72 87 112 66 81 116 66 82 112 60 77 
14 A 112 72 84 112 68 82 88 56 65 98 64 75 94 62 72 
15 A 104 68 80 102 66 78 100 60 73 106 68 80 100 66 77 
16 A 98 60 72 96 64 85 100 64 76 102 62 75 102 68 79 
17 A 94 62 72 98 60 72 100 60 73 116 64 81 112 64 80 
18 A 98 54 68 92 52 65 98 60 72 100 66 77 112 64 80 
19 A 112 70 85 108 62 77 102 60 74 106 60 74 100 64 76 
20 A 100 68 78 90 52 65 96 54 68 90 54 66 100 58 72 
21 A 128 72 90 118 70 86 106 68 80 104 64 77 112 60 77 
22 A 100 52 68 102 52 68 106 50 68 102 54 70 104 52 69 
23 A 112 66 81 112 60 77 100 62 74 102 62 75 106 60 75 
24 A 114 68 83 102 66 78 100 60 73 104 60 74 100 60 73 
25 A 108 70 82 98 66 76 104 68 80 100 66 77 102 64 76 
26 A 114 68 83 112 66 81 102 62 75 102 60 74 100 60 73 
27 A 90 52 65 96 56 69 100 54 68 98 56 70 100 64 76 
28 A 94 66 75 108 68 81 112 68 82 100 66 77 106 70 82 
29 A 102 60 74 104 68 80 100 62 74 106 60 75 100 64 76 
30 A 104 66 80 102 62 75 100 60 73 106 68 80 108 66 80 
S.No Group 20 MIN SBP 
20 MIN 
DBP 
20 MIN 
MAP 
25 MIN 
SBP 
25 MIN 
DBP 
25 MIN 
MAP 
30 MIN 
SBP 
30 MIN 
DBP 
30 MIN 
MAP 
45 MIN 
SBP 
45 MIN 
DBP 
45 MIN 
MAP 
60 MIN 
SBP 
60 MIN 
DBP 
60 MIN 
MAP 
1 B 124 74 90 120 72 88 120 74 89 118 72 87 124 80 94 
2 B 120 70 86 106 62 76 108 66 80 116 68 84 114 68 83 
3 B 108 66 80 100 62 74 98 62 74 112 68 82 114 68 72 
4 B 118 66 84 112 68 82 112 68 82 108 68 81 124 70 88 
5 B 102 56 71 92 52 65 98 52 67 94 50 65 108 58 74 
6 B 124 74 90 124 70 88 124 72 89 122 74 90 124 72 89 
7 B 104 68 81 108 70 82 118 70 86 112 70 84 118 72 87 
8 B 124 74 90 124 72 89 122 72 88 124 74 90 122 78 92 
9 B 112 70 83 114 68 82 112 70 84 112 68 82 108 68 81 
10 B 114 68 82 90 56 67 98 62 72 100 66 72 102 66 78 
11 B 128 74 92 124 80 94 122 86 98 124 80 94 132 82 98 
12 B 130 80 96 132 82 98 124 80 94 124 78 93 124 80 94 
13 B 118 72 87 120 72 88 116 76 89 118 70 86 118 72 87 
14 B 126 70 88 120 70 86 106 62 76 108 68 81 116 68 84 
15 B 104 68 80 102 70 80 106 72 83 122 72 88 124 80 94 
16 B 122 70 87 102 66 78 108 70 82 112 72 84 122 74 90 
17 B 108 68 81 92 54 66 98 56 70 92 52 65 98 64 75 
18 B 120 72 90 112 70 84 114 72 86 112 70 84 122 74 90 
19 B 118 70 86 118 70 86 124 72 89 124 74 90 122 72 89 
20 B 92 54 66 98 56 70 96 54 68 98 60 72 100 68 78 
21 B 128 82 97 124 80 94 112 70 84 104 68 80 120 74 89 
22 B 116 76 89 102 64 76 100 58 72 108 68 81 118 70 86 
23 B 128 78 94 124 80 94 126 76 91 128 80 95 124 78 92 
24 B 116 78 90 110 72 84 108 68 81 112 70 84 106 68 80 
25 B 98 60 72 100 72 81 104 72 82 106 72 83 106 70 82 
26 B 124 80 94 122 74 90 112 72 84 112 70 83 112 72 84 
27 B 108 68 81 112 68 82 104 68 81 108 70 82 112 70 84 
28 B 126 78 94 116 80 92 122 78 92 126 80 95 124 82 96 
29 B 120 72 88 108 68 81 106 68 80 100 72 81 112 70 84 
30 B 120 70 86 106 62 76 108 68 81 116 68 84 114 68 83 
 
  
BLOOD PRESSURE (Contd…) 
 
S.No Group 75 MIN SBP 
75 MIN 
DBP 
75 MIN 
MAP 
90 MIN 
SBP 
90 MIN 
DBP 
90 MIN 
MAP 
120 MIN 
SBP 
120 MIN 
DBP 
120 MIN 
MAP 
150 MIN 
SBP 
150 MIN 
DBP 
150 MIN 
MAP 
180 MIN 
SBP 
180 MIN 
DBP 
180 MIN 
MAP 
1 A 120 64 82 122 72 89 124 72 89 120 78 92 124 80 94 
2 A 112 68 82 124 76 92 112 72 85 124 72 89 126 80 95 
3 A 112 68 82 122 70 87 124 72 89 124 80 100 132 86 101 
4 A 114 70 84 124 72 89 122 74 90 124 80 94 122 86 98 
5 A 112 68 82 122 74 90 120 70 86 132 80 97 128 88 101 
6 A 122 70 87 120 72 88 122 78 92 124 74 90 124 80 94 
7 A 100 62 74 116 68 84 100 64 76 118 72 87 124 74 90 
8 A 112 64 80 118 70 86 120 70 87 124 72 89 124 74 90 
9 A 108 70 82 122 74 90 114 72 86 124 80 94 122 86 98 
10 A 100 68 78 112 78 89 118 72 87 124 78 93 124 80 94 
11 A 108 68 81 118 70 86 122 74 90 124 80 94 126 80 95 
12 A 112 70 84 112 70 84 116 78 90 126 80 95 122 86 98 
13 A 100 58 72 116 68 84 118 68 84 122 74 90 124 78 92 
14 A 100 68 78 112 70 84 118 76 90 124 72 89 124 78 93 
15 A 112 68 82 112 68 82 124 80 94 118 72 87 124 78 92 
16 A 112 70 84 112 68 82 118 76 90 124 80 94 128 88 101 
17 A 98 66 76 108 68 81 112 70 84 124 78 93 124 80 94 
18 A 100 64 76 112 66 81 118 68 84 126 80 95 122 86 98 
19 A 102 64 77 120 68 85 124 78 92 124 80 94 124 80 100 
20 A 112 60 77 112 68 82 112 76 88 124 80 94 128 88 101 
21 A 116 68 84 120 70 86 120 72 88 124 72 89 124 78 93 
22 A 120 60 80 112 68 82 120 72 88 124 80 94 122 74 90 
23 A 112 60 77 116 64 81 118 70 86 124 78 93 126 80 95 
24 A 112 64 80 118 68 84 124 78 92 126 80 95 124 80 100 
25 A 104 68 80 112 70 84 124 78 93 122 86 98 122 86 98 
26 A 120 60 80 118 68 84 128 88 101 124 80 94 128 88 101 
27 A 112 68 82 112 68 82 112 70 84 118 76 90 122 74 90 
28 A 112 68 82 124 72 89 112 70 84 118 72 87 122 74 90 
29 A 118 68 84 112 68 82 124 78 93 124 80 94 126 80 95 
30 A 112 68 82 112 70 84 124 74 90 124 78 92 126 80 95 
S.No Group 75 MIN SBP 
75 MIN 
DBP 
75 MIN 
MAP 
90 MIN 
SBP 
90 MIN 
DBP 
90 MIN 
MAP 
120 MIN 
SBP 
120 MIN 
DBP 
120 MIN 
MAP 
150 MIN 
SBP 
150 MIN 
DBP 
150 MIN 
MAP 
180 MIN 
SBP 
180 MIN 
DBP 
180 MIN 
MAP 
1 B 128 82 97 126 80 95 120 78 92 124 80 94 132 86 101 
2 B 132 70 90 120 70 86 124 80 94 128 88 101 132 88 103 
3 B 122 74 90 124 78 92 124 72 89 122 74 90 124 80 94 
4 B 122 72 88 128 74 92 124 74 90 124 72 89 124 78 92 
5 B 112 60 77 118 70 86 124 72 89 118 72 87 124 74 90 
6 B 132 80 97 124 82 96 112 72 85 124 80 94 122 86 98 
7 B 122 74 90 124 74 90 124 72 89 124 78 93 124 80 94 
8 B 124 78 93 124 80 94 122 74 90 126 80 95 126 80 95 
9 B 124 72 89 124 78 93 120 70 86 124 80 94 128 88 101 
10 B 104 68 80 118 72 87 122 78 92 124 80 94 124 78 93 
11 B 136 88 104 132 86 101 100 64 76 132 82 98 132 86 101 
12 B 128 88 101 132 82 98 120 70 87 124 80 94 124 78 93 
13 B 112 70 84 124 78 93 114 72 86 124 74 90 120 78 92 
14 B 114 68 72 112 70 84 118 72 87 112 70 84 114 74 87 
15 B 124 78 93 122 74 90 122 74 90 126 80 95 132 80 97 
16 B 124 72 89 124 72 89 116 78 90 132 72 92 132 82 98 
17 B 96 68 77 108 70 84 118 68 84 118 70 86 118 72 87 
18 B 124 78 93 122 78 92 118 76 90 134 80 98 132 80 97 
19 B 124 72 89 124 76 92 124 80 94 124 78 93 124 80 94 
20 B 108 68 81 112 70 84 124 78 93 124 80 94 124 80 94 
21 B 120 78 92 122 70 87 124 78 92 124 72 89 124 78 92 
22 B 122 72 89 124 76 92 120 78 92 124 80 94 126 80 95 
23 B 124 80 94 120 78 92 124 80 94 126 80 95 132 82 98 
24 B 112 72 84 124 78 93 124 80 94 132 80 97 122 86 98 
25 B 112 70 84 114 74 87 118 72 87 124 72 89 124 74 90 
26 B 124 80 94 126 78 94 126 80 95 122 86 98 132 86 101 
27 B 124 72 89 112 70 84 112 78 89 122 74 90 124 72 89 
28 B 130 88 102 124 78 93 134 80 98 132 86 101 132 82 98 
29 B 128 78 94 124 78 92 122 78 92 124 80 94 124 76 92 
30 B 132 72 92 120 70 86 126 76 91 124 78 93 120 78 92 
 
  
OXYGEN SATURATION (%) 
 
S.No Group BASE LINE 20 MIN 5 MIN 10 MIN 15 MIN 20 MIN 25 MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 150 MIN 180 MIN 
1 A 100 100 100 100 100 99 99 100 98 99 99 99 99 100 100 
2 A 100 100 100 100 100 99 99 99 99 99 99 99 100 100 100 
3 A 100 100 100 100 100 100 100 98 99 99 98 99 100 100 100 
4 A 100 100 100 100 100 99 99 100 100 100 100 100 100 100 100 
5 A 99 99 99 99 99 100 98 99 100 100 99 100 99 100 100 
6 A 100 100 100 100 100 98 99 99 99 99 100 100 100 100 100 
7 A 100 99 99 100 100 99 100 99 99 100 100 99 100 100 100 
8 A 100 100 100 100 100 99 99 100 100 100 100 100 99 100 100 
9 A 98 100 100 100 98 99 99 98 99 99 98 99 98 99 100 
10 A 99 100 100 99 99 99 100 100 100 100 99 99 100 100 100 
11 A 99 98 100 100 100 99 100 100 100 100 100 100 100 100 100 
12 A 100 100 100 100 99 99 100 100 100 100 100 100 100 100 100 
13 A 100 100 100 99 100 100 99 100 100 100 100 100 99 100 100 
14 A 100 99 100 100 100 99 99 100 100 100 100 100 100 99 100 
15 A 100 100 100 100 100 100 100 99 99 100 99 100 100 100 100 
16 A 98 99 100 99 99 100 100 99 99 100 99 99 100 100 100 
17 A 100 100 99 100 100 99 99 100 99 99 100 99 100 100 100 
18 A 99 99 99 98 99 99 100 100 99 100 99 100 99 100 100 
19 A 99 99 100 100 99 99 99 100 100 99 99 100 99 100 100 
20 A 100 100 100 100 100 100 100 100 100 99 100 99 99 100 100 
21 A 100 100 100 99 100 98 100 100 98 99 99 99 99 100 100 
22 A 100 100 100 99 100 99 100 99 100 99 99 99 99 100 100 
23 A 100 100 99 99 99 99 99 99 99 99 99 100 100 100 100 
24 A 100 100 98 99 100 100 100 100 100 99 99 99 100 99 100 
25 A 100 100 99 99 99 99 100 99 99 100 100 100 100 100 100 
26 A 99 98 99 99 99 99 99 99 99 99 99 99 99 98 99 
27 A 99 99 99 99 99 99 99 99 99 99 99 99 99 99 99 
28 A 100 100 100 99 99 99 99 99 99 100 100 100 99 100 100 
29 A 100 99 100 100 99 100 100 99 100 99 99 99 100 100 100 
30 A 100 99 99 98 98 98 98 99 99 100 100 100 100 100 100 
S.No Group BASE LINE 20 MIN 5 MIN 10 MIN 15 MIN 20 MIN 25 MIN 30 MIN 45 MIN 60 MIN 75 MIN 90 MIN 120 MIN 150 MIN 180 MIN 
1 B 100 100 100 100 100 100 100 100 99 100 100 100 99 100 100 
2 B 100 99 100 100 100 100 100 100 100 99 99 99 100 100 100 
3 B 100 100 100 100 100 99 100 100 100 100 100 100 100 100 100 
4 B 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
5 B 99 100 100 100 100 100 100 100 100 100 100 99 100 100 100 
6 B 100 100 100 100 100 100 99 100 100 99 99 98 100 100 100 
7 B 99 99 100 99 100 99 99 100 99 100 100 99 100 100 100 
8 B 100 100 100 100 99 100 100 100 100 100 99 100 100 100 100 
9 B 100 99 99 100 99 99 100 99 99 99 99 100 100 100 100 
10 B 100 100 100 100 100 100 99 100 100 99 99 100 98 100 100 
11 B 100 100 100 100 100 100 100 100 100 100 99 99 99 100 100 
12 B 100 99 99 100 98 99 99 98 99 99 100 100 100 100 100 
13 B 100 99 99 99 100 99 99 100 99 100 99 99 100 100 100 
14 B 100 99 98 99 99 99 99 98 99 100 99 99 100 100 100 
15 B 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
16 B 100 100 100 99 100 100 100 99 100 99 98 99 100 100 100 
17 B 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
18 B 99 99 99 99 99 99 99 99 99 0.97 98 99 99 98 100 
19 B 100 100 100 100 100 100 100 100 100 100 100 100 99 100 100 
20 B 100 99 99 98 99 98 99 98 99 99 100 100 100 100 100 
21 B 100 100 99 100 100 98 100 100 99 100 100 100 100 100 100 
22 B 100 98 100 100 100 100 100 100 100 100 100 100 100 100 100 
23 B 100 100 100 100 99 99 99 99 100 100 100 100 100 100 100 
24 B 100 100 100 100 100 100 100 100 100 100 100 100 100 100 100 
25 B 99 99 100 100 100 100 100 100 100 99 99 100 100 100 100 
26 B 100 100 100 99 99 100 99 100 100 100 100 100 100 100 100 
27 B 99 98 99 99 99 99 99 99 99 99 99 99 98 100 100 
28 B 100 100 100 99 99 99 100 99 99 99 99 100 100 100 100 
29 B 100 100 99 100 100 100 100 99 100 100 100 100 100 100 100 
30 B 99 100 100 99 98 100 100 100 99 100 100 99 99 100 100 
 
